Threat from Emerging Vectorborne Viruses

Emerging Infectious Diseases
Volume 22, Number 5—May 2016
http://wwwnc.cdc.gov/eid/

.
Commentary
Threat from Emerging Vectorborne Viruses
Ronald Rosenberg
Author affiliation: Centers for Disease Control and Prevention, Fort Collins, Colorado, USA
The earliest members of genus Homo were surely bedeviled by blood-feeding arthropods, some of which doubtless carried zoonotic pathogens. However, the phenomenon of vectorborne human epidemic disease began only after humans began building settlements 15,000 years ago (1). Settlements offered pathogens not only host density but also opportunities for their vertebrate reservoirs and arthropod vectors to cohabit with us. Epidemic Yersinia pestis (the Medieval Black Death) was only possible because black rats (Rattus rattus), the host of the vector flea, had become extraordinarily successful at living off human garbage and nesting in our buildings.

Two of the most important malaria vectors in the world exploit human activity to proliferate. Immature forms of Anopheles gambiae mosquitoes in Africa and An. dirus mosquitoes in Southeast Asia thrive in the small puddles (water-filled footprints, tire ruts, borrow pits, and drainage gullies) created around villages. Best adapted of all are Aedes aegypti mosquitoes, the cosmopolitan vector of epidemic yellow fever, dengue, chikungunya, and Zika viruses. Their ecologic niche is nearly ours.

These mosquitoes lay eggs in artifacts: water storage jars, roof gutters, flower pots, dog dishes, even upturned bottle caps. Their cognate species, Ae. albopictus, is only slightly less versatile, having an attraction to discarded tires. Evolution of blood-feeding arthropods to our changing environment and evolution of some zoonoses to exploit this advantage are major links in the emergence of obscure pathogens into epidemic threats and is a timely subject for this issue of Emerging Infectious Diseases.
Persistence of human yellow fever, the seeming inexorable expansion of dengue, and the surprising, explosive spread and severity of first chikungunya virus and now Zika virus bear testament to the threat posed by habituated Aedes species. Since its arrival in the Western Hemisphere ≈1 year ago, Zika virus, which had previously been associated with a clinically mild and inconsequential illness, is now increasingly suspected of being the cause of an alarming epidemic of neurologic birth defects and Guillain-Barré syndrome in tropical regions. Zika virus, the subject of several articles in this issue, reminds us of some of the impediments to responding to emerging vectorborne pathogens.

First, Zika virus belongs to the most prevalent class of emerging pathogens, the zoonotic single-stranded RNA viruses, which have mutation rates as high as 1 base/104 bases each replication. The chikungunya pandemic that began 10 years ago was fueled in part by a single, nonsynonymous base change that enabled that alphavirus to replicate more efficiently in Ae. albopictus mosquitoes (2).

Second, conditions enabling transition from vectorborne animal-to-animal transmission to arthropod-mediated human-to-human transmission are poorly understood. Like dengue virus, another flavivirus, Zika virus was likely originally a pathogen of subhuman primates. Between its discovery in a sentinel macaque in Uganda in 1947 and the first recorded epidemic 60 years later in Yap, Federated States of Micronesia, only 14 human cases had been reported, all from Africa and Asia (3).

Third, the pathogenicity and transmission dynamics of vectorborne zoonotic pathogens are much more complex than those of directly communicable pathogens. It is not yet known if Zika virus will find sustaining, nonhuman hosts in the Western Hemisphere, as has yellow fever virus, or how wide the range of vector species will be. Pathogenicity and transmission dynamics will be factors in determining where Zika virus will become endemic and what will be the most suitable methods of control.
Fourth, accurate diagnosis is key to surveillance and response. It might seem as if Zika virus sprang from nowhere, but almost certainly it must have been infecting many more humans in Africa and Asia than we had been aware. Our ability to serologically diagnose infections with emerging arboviruses is often compromised by close antigenic relationships within virus families. Zika, dengue, West Nile, and yellow fever viruses can co-circulate, not only among themselves, but possibly with unidentified or poorly characterized flaviviruses. The limitations of current diagnostics are a primary reason why the association between Zika virus and birth defects remained speculative so long.

Fifth, vector control is a force multiplier that can reduce the risk from many viruses that would require the development of individual vaccines. However, insecticide resistance and application problems greatly impede effective implementation.
The best defense is preventing a problem from growing into a threat. Fewer than 20 of the 86 known pathogenic arboviruses can be considered major causes of human disease, and 3 of these, West Nile, chikungunya, and Zika viruses, have emerged from relative obscurity within only the past 20 years (4). At least another 200 cataloged arboviruses whose relationship to human disease is unknown have been isolated from arthropods or animals.

The discovery of 3 highly pathogenic mosquitoborne viruses in China and the United States during the past 5 years (5–7) underscores how unrepresentative even that large number might be. It is unrealistic to characterize each of these viruses. Besides needing better methods of vector control, we need a strategy for preemptively identifying arboviruses with the potential for emergence and to devote resources to better understand their transmission dynamics, their endemicity, and accurate diagnosis.

Dr. Rosenberg is on the staff of the National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins. Colorado.
References available at link above.

Globalization and Health [Accessed 14 May 2016]

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 14 May 2016]
.
Research
The use of technology enhanced learning in health research capacity development: lessons from a cross country research partnership
E. Byrne, L. Donaldson, L. Manda-Taylor, R. Brugha, A. Matthews, S. MacDonald, V. Mwapasa, M. Petersen and A. Walsh
Globalization and Health 2016 12:19
Published on: 10 May 2016
Abstract
Background
With the recognition of the need for research capacity strengthening for advancing health and development, this research capacity article explores the use of technology enhanced learning in the delivery of a collaborative postgraduate blended Master’s degree in Malawi. Two research questions are addressed: (i) Can technology enhanced learning be used to develop health research capacity?, and: (ii) How can learning content be designed that is transferrable across different contexts?
Methods
An explanatory sequential mixed methods design was adopted for the evaluation of technology enhanced learning in the Masters programme. A number of online surveys were administered, student participation in online activities monitored and an independent evaluation of the programme conducted.
Results
Remote collaboration and engagement are paramount in the design of a blended learning programme and support was needed for selecting the most appropriate technical tools. Internet access proved problematic despite developing the content around low bandwidth availability and training was required for students and teachers/trainers on the tools used. Varying degrees of engagement with the tools used was recorded, and the support of a learning technologist was needed to navigate through challenges faced.
Conclusion
Capacity can be built in health research through blended learning programmes. In relation to transferability, the support required institutionally for technology enhanced learning needs to be conceptualised differently from support for face-to-face teaching. Additionally, differences in pedagogical approaches and styles between institutions, as well as existing social norms and values around communication, need to be embedded in the content development if the material is to be used beyond the pilot resource-intensive phase of a project.
.

Research
Analysis of the corporate political activity of major food industry actors in Fiji
Non-communicable diseases (NCDs) are the leading cause of mortality in Fiji, a middle-income country in the Pacific. Some food products processed sold and marketed by the food industry are major contributors t…
Melissa Mialon, Boyd Swinburn, Jillian Wate, Isimeli Tukana and Gary Sacks
Globalization and Health 2016 12:18
Published on: 10 May 2016
Abstract
Background
Non-communicable diseases (NCDs) are the leading cause of mortality in Fiji, a middle-income country in the Pacific. Some food products processed sold and marketed by the food industry are major contributors to the NCD epidemic, and the food industry is widely identified as having strong economic and political power. However, little research has been undertaken on the attempts by the food industry to influence public health-related policies and programs in its favour. The “corporate political activity” (CPA) of the food industry includes six strategies (information and messaging; financial incentives; constituency building; legal strategies; policy substitution; opposition fragmentation and destabilisation). For this study, we aimed to gain a detailed understanding of the CPA strategies and practices of major food industry actors in Fiji, interpreted through a public health lens.
Methods and results
We implemented a systematic approach to monitor the CPA of the food industry in Fiji for three months. It consisted of document analysis of relevant publicly available information. In parallel, we conducted semi-structured interviews with 10 stakeholders involved in diet- and/or public health-related issues in Fiji. Both components of the study were thematically analysed. We found evidence that the food industry adopted a diverse range of strategies in an attempt to influence public policy in Fiji, with all six CPA strategies identified. Participants identified that there is a substantial risk that the widespread CPA of the food industry could undermine efforts to address NCDs in Fiji.
Conclusions
Despite limited public disclosure of information, such as data related to food industry donations to political parties and lobbying, we were able to identify many CPA practices used by the food industry in Fiji. Greater transparency from the food industry and the government would help strengthen efforts to increase their accountability and support NCD prevention. In other low- and middle-income countries, it is likely that a systematic document analysis approach would also need to be supplemented with key informant interviews to gain insight into this important influence on NCD prevention.

Health Affairs – May 2016

Health Affairs
May 2016; Volume 35, Issue 5
http://content.healthaffairs.org/content/current
.
Prescription Drugs, Global Health & More
From The Editor-in-Chief
Prescription Drugs, Global Health, And Population Health
Alan R. Weil
This month’s issue of Health Affairs covers a broad range of topics. We begin with prescription drugs, noting the recent report from IMS Health that drug spending increased by 8.5 percent in 2015.
Prescription Drugs
Unit prices for cancer drugs are higher in the United States than other developed countries. Sebastian Salas-Vega and Elias Mossialos compare the value in lives saved for cancer drug spending in nine countries, including the United States. Assigning a standard value for extended life-years, the authors calculate a $32.6 billion net positive return from cancer drug care in 2014 in the United States—a lower return per dollar spent than in all other countries analyzed. Japan achieved almost seven times the US rate of return.
Anomalies in the US drug market often yield price increases over time after a drug has been released. Caroline Bennette and colleagues set out to understand why. Analyzing data for twenty-four cancer drugs over six …
.
Global Health
Improving Health Care Coverage, Equity, And Financial Protection Through A Hybrid System: Malaysia’s Experience
Ravindra P. Rannan-Eliya, Chamara Anuranga, Adilius Manual, Sondi Sararaks, Anis S. Jailani,
Abdul J. Hamid, Izzanie M. Razif, Ee H. Tan, and Ara Darzi
Author Affiliations
1Ravindra P. Rannan-Eliya (raviofficelk@gmail.com) is executive director of the Institute for Health Policy, in Colombo, Sri Lanka.
2Chamara Anuranga is a research associate at the Institute for Health Policy.
3Adilius Manual is a research officer at the Institute for Health Systems Research, National Institutes of Health (NIH), in Selangor, Malaysia.
4Sondi Sararaks is a senior medical officer at the Institute for Health Systems Research, NIH, Malaysia.
5Anis S. Jailani is a research officer at the Institute for Health Systems Research, NIH, Malaysia.
6Abdul J. Hamid is a research officer at the Institute for Health Systems Research, NIH, Malaysia.
7Izzanie M. Razif is a research officer in the National Health Financing Unit of the Ministry of Health, in Putrajaya, Malaysia.
8Ee H. Tan is senior principal assistant director of the Oral Health Division of the Ministry of Health, in Putrajaya.
9Ara Darzi is executive chair of the World Innovation Summit for Health, Qatar Foundation, and director of the Institute of Global Health Innovation, Imperial College London, in the United Kingdom.
Abstract
Malaysia has made substantial progress in providing access to health care for its citizens and has been more successful than many other countries that are better known as models of universal health coverage. Malaysia’s health care coverage and outcomes are now approaching levels achieved by member nations of the Organization for Economic Cooperation and Development. Malaysia’s results are achieved through a mix of public services (funded by general revenues) and parallel private services (predominantly financed by out-of-pocket spending). We examined the distributional aspects of health financing and delivery and assessed financial protection in Malaysia’s hybrid system. We found that this system has been effective for many decades in equalizing health care use and providing protection from financial risk, despite modest government spending. Our results also indicate that a high out-of-pocket share of total financing is not a consistent proxy for financial protection; greater attention is needed to the absolute level of out-of-pocket spending. Malaysia’s hybrid health system presents continuing unresolved policy challenges, but the country’s experience nonetheless provides lessons for other emerging economies that want to expand access to health care despite limited fiscal resources.

Health Policy and Planning – Volume 31 Issue 5 June 2016

Health Policy and Planning
Volume 31 Issue 5 June 2016
http://heapol.oxfordjournals.org/content/current
.
Original Articles
The composition of demand for newly launched vaccines: results from the pneumococcal and rotavirus vaccine introductions in Ethiopia and Malawi
B Adam Williams, Teklay Kidane, Geoffrey Chirwa, Neghist Tesfaye, Marta R Prescott, Soleine T Scotney, Moussa Valle, Sintayehu Abebe, Adija Tambuli, Bridget Malewezi, Tahir Mohammed, Emily Kobayashi, Emily Wootton, Renee Wong, Rahima Dosani, Hamsa Subramaniam, Jessica Joseph, Elif Yavuz, Aliza Apple, Yann Le Tallec, and Alice Kang’ethe
Health Policy Plan. (2016) 31 (5): 563-572 doi:10.1093/heapol/czv103
Abstract
Understanding post-launch demand for new vaccines can help countries maximize the benefits of immunization programmes. In particular, low- and middle-income countries (LMICs) should ensure adequate resource planning with regards to stock consumption and service delivery for new vaccines, whereas global suppliers must produce enough vaccines to meet demand. If a country underestimates the number of children seeking vaccination, a stock-out of commodities will create missed opportunities for saving lives. We describe the post-launch demand for the first dose of pneumococcal conjugate vaccine (PCV1) in Ethiopia and Malawi and the first dose of rotavirus vaccine (Rota1) in Malawi, with focus on the new birth cohort and the ‘backlog cohort’, comprised of older children who are still eligible for vaccination at the time of launch. PCV1 and Rota1 uptake were compared with the demand for the first dose of pentavalent vaccine (Penta1), a routine immunization that targets the same age group and immunization schedule. In the first year, the total demand for PCV1 was 37% greater than that of Penta1 in Ethiopia and 59% greater in Malawi. In the first 6 months, the demand of Rota1 was only 5.9% greater than Penta1 demand in Malawi. Over the first three post-introduction months, 70.7% of PCV1 demand in Ethiopia and 71.5% of demand in Malawi came from children in the backlog cohort, whereas only 28.0% of Rota1 demand in Malawi was from the backlog cohort. The composition of demand was impacted by time elapsed since vaccine introduction and age restrictions. Evidence suggests that countries’ plans should account for the impact of backlog demand, especially in the first 3 months post-introduction. LMICs should request for higher stock volumes when compared with routine needs, plan social mobilization activities to reach the backlog cohort and allocate human resources and cold chain capacity to accommodate high demand following vaccine introduction.
.
Resource needs and gap analysis in achieving universal access to HIV/AIDS services: a data envelopment analysis of 45 countries
Wu Zeng, Donald S Shepard, Carlos Avila-Figueroa, and Haksoon Ahn
Abstract
Background—To manage the human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS) epidemic, international donors have pledged unprecedented commitments for needed services. The Joint United Nations Programme on HIV/AIDS (UNAIDS) projected that low- and middle-income countries needed $25 billion to meet the 2010 HIV/AIDS goal of universal access to AIDS prevention and care, using the resource needs model (RNM).
Methods—Drawing from the results from its sister study, which used a data envelopment analysis (DEA) and a Tobit model to evaluate and adjust the technical efficiency of 61 countries in delivering HIV/AIDS services from 2002 to 2007, this study extended the DEA and developed an approach to estimate resource needs and decompose the performance gap into efficiency gap and resource gap. In the DEA, we considered national HIV/AIDS spending as the input and volume of voluntary counseling and testing (VCT), prevention of mother to child transmission (PMTCT) and antiretroviral treatment (ART) as the outputs. An input-oriented DEA model was constructed to project resource needs in achieving 2010 HIV/AIDS goal for 45 countries using the data in 2006, assuming that all study countries maximized efficiency.
Findings—The DEA approach demonstrated the potential to include efficiency of national HIV/AIDS programmes in resource needs estimation, using macro-level data. Under maximal efficiency, the annual projected resource needs for the 45 countries was $6.3 billion, ∼47% of their UNAIDS estimate of $13.5 billion. Given study countries’ spending of $3.9 billion, improving efficiency could narrow the gap from $9.6 to $2.4 billion. The results suggest that along with continued financial commitment to HIV/AIDS, improving the efficiency of HIV/AIDS programmes would accelerate the pace to reach 2010 HIV/AIDS goals. The DEA approach provides a supplement to the AIDS RNM to inform policy making.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines) Volume 12, Issue 4, 2016

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 12, Issue 4, 2016
http://www.tandfonline.com/toc/khvi20/current
.
Reviews
Vaccines in pregnancy: The dual benefit for pregnant women and infants
pages 848-856
H. Marshall, M. McMillan, R. M. Andrews, K. Macartney & K. Edwards
ABSTRACT
Maternal immunization has the potential to reduce the burden of infectious diseases in the pregnant woman and her infant. Many countries now recommend immunization against influenza at any stage of pregnancy and against pertussis in the third trimester. Despite evidence of the safety and effectiveness of these vaccines when administered during pregnancy, uptake generally remains low for influenza and moderate for pertussis vaccine. Enhancing confidence in both immunization providers and pregnant women by increasing the evidence-base for the safety and effectiveness of vaccines during pregnancy, improving communication and access by incorporating immunization into standard models of antenatal care are likely to improve uptake. Developing a framework for implementation of vaccines for pregnant women which is cognizant of local and national cultural, epidemiological, behavioral and societal factors will enable a smooth transition and high uptake for new vaccines currently in development for pregnant women.
.
Reviews
Improving rates of maternal immunization: Challenges and opportunities
pages 857-865
Donna M. MacDougall & Scott A. Halperin
ABSTRACT
Objectives: An increasing number of vaccines are recommended or are being developed for use during pregnancy to protect women, fetuses, and/or newborns. For vaccines that are already recommended, vaccine uptake is variable and well below desired target. We reviewed the literature related to factors that affect a healthcare provider’s recommendation and a woman’s willingness to be vaccinated during pregnancy. Design: A scoping review of published literature from 2005 to 2015 was undertaken and all relevant articles were abstracted, summarized, and organized thematically. Results: Barriers and facilitators were identified that either decreased or increased the likelihood of a healthcare provider offering and a pregnant woman accepting vaccination during pregnancy. Concern about the safety of vaccines given during pregnancy was the most often cited barrier among both the public and healthcare providers. Other barriers included doubt about the effectiveness of the vaccine, lack of knowledge about the burden of disease, and not feeling oneself to be at risk of the infection. Major facilitators for maternal immunization included specific safety information about the vaccine in pregnant women, strong national recommendations, and healthcare providers who both recommended and provided the vaccine to their patients. Systems barriers such as inadequate facilities and staffing, vaccine purchase and storage, and reimbursement for vaccination were also cited. Evidence-based interventions were few, and included text messaging reminders, chart reminders, and standing orders. Conclusions: In order to have an effective vaccination program, improvements in the uptake of recommended vaccines during pregnancy are needed. A maternal immunization platform is required that normalizes vaccination practice among obstetrical care providers and is supported by basic and continuing education, communication strategy, and a broad range of research.
.
Research Papers
Knowledge, attitudes, beliefs, and behaviors of pregnant women approached to participate in a Tdap maternal immunization randomized, controlled trial
Open access
DOI:10.1080/21645515.2015.1130193
Donna M. MacDougallab*, Beth A. Halperinacd, Joanne M. Langleyade, Shelly A. McNeilaf, Donna MacKinnon-Camerona, Li Lia & Scott A. Halperin
pages 879-885
ABSTRACT
Immunization with pertussis vaccine during pregnancy is recommended in a number of countries to prevent newborn deaths from whooping cough. In some jurisdictions, vaccine uptake during pregnancy is low. We undertook a survey of the knowledge, attitudes, beliefs, and behaviors of pregnant women who had been approached to participate in a randomized, controlled trial of tetanus-diphtheria-acellular pertussis (Tdap) vaccine during pregnancy. A total of 346 women completed the survey. Knowledge about pertussis and pertussis vaccine was generally low; the mean number of correct answers was 10.65 out of 19 questions. Attitudes toward maternal immunization were generally favorable; 51.7%–94.7% of women had positive responses to 10 attitudinal statements. Substantial uncertainty was shown in responses to a number of the attitudinal statements related to vaccination during pregnancy; 22.3%–45.7% neither agreed nor disagreed with the statements. Importantly, 89% of women reported that they would get immunized with pertussis vaccine during pregnancy if their physician recommended it. We conclude that a national recommendation to be immunized with pertussis vaccine during pregnancy supported by their physicians’ recommendation would be well received by Canadian women.
.
Review
Current status of new tuberculosis vaccine in children
DOI:10.1080/21645515.2015.1120393
Yu Pangab#, Aihua Zhaoc#, Chad Cohend, Wanli Kanga, Jie Lue, Guozhi Wangc, Yanlin Zhaob & Suhua Zhenga*
pages 960-970
ABSTRACT
Pediatric tuberculosis contributes significantly to the burden of TB disease worldwide. In order to achieve the goal of eliminating TB by 2050, an effective TB vaccine is urgently needed to prevent TB transmission in children. BCG vaccination can protect children from the severe types of TB such as TB meningitis and miliary TB, while its efficacy against pediatric pulmonary TB ranged from no protection to very high protection. In recent decades, multiple new vaccine candidates have been developed, and shown encouraging safety and immunogenicity in the preclinical experiments. However, the limited data on protective efficacy in infants evaluated by clinical trials has been disappointing, an example being MVA85A. To date, no vaccine has been shown to be clinically safer and more effective than the presently licensed BCG vaccine. Hence, before a new vaccine is developed with more promising efficacy, we must reconsider how to better use the current BCG vaccine to maximize its effectiveness in children.
.
Research Paper
U.S. Immunization program adult immunization activities and resources
DOI:10.1080/21645515.2015.1109756
LaDora O. Woodsa*, Carolyn B. Bridgesb, Samuel B. Graitcerc & Brock Lamontc
pages 1045-1050
ABSTRACT
Adults are recommended to receive vaccines based on their age, medical conditions, prior vaccinations, occupation and lifestyle. However, adult immunization coverage is low in the United States and lags substantially below Healthy People 2020 goals. To assess activities and resources designated for adult immunization programs by state and local health department immunization programs in the United States, we analyzed 2012 and 2013 data from the Centers for Disease Control and Prevention’s (CDC) Program Annual Reports and Progress Assessments (PAPA) survey of CDC-funded immunization programs. Fifty-six of 64 funded US immunization programs’ responses were included in the analysis. Eighty-two percent of (n = 46) programs reported having a designated adult immunization coordinator in 2012 and 73% (n = 41) in 2013. Of the 46 coordinators reported in 2012, 30% (n = 14) spent more than 50% of their time on adult immunization activities, and only 24% (n = 10) of the 41 adult coordinators in 2013 spent more than 50% of their time on adult immunization activities. In 2012, 23% (n = 13) of the 56 programs had a separate immunization coalition for adults and 68% (n = 38) included adult issues in their overall immunization program coalition. In 2013, 25% (n = 14) had a separate adult immunization coalition while 57% (n = 32) incorporated adult immunizations into their overall immunization program coalition. The results indicate substantial variation across the US in public health infrastructure to support adult immunizations. Continued assessment of adult immunization resources and activities will be important in improving adult immunization coverage levels though program support. With many programs having limited resources dedicated to improving adult immunization rates in the in US, efforts by the health departments to collaborate with providers and other partners in their jurisdictions to increase awareness, increase the use of proven strategies to improve vaccination of adults, and implement the Standards for Adult Immunization Practice may lead to improved adult immunization coverage and fewer illnesses, hospitalizations and deaths from vaccine preventable diseases.

Prevalence of chronic infections and susceptibility to measles and varicella-zoster virus in Latin American immigrants

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 14 May 2016]

.
Research Article
Prevalence of chronic infections and susceptibility to measles and varicella-zoster virus in Latin American immigrants
Yves Jackson, Lilian Santos, Isabelle Arm-Vernez, Anne Mauris, Hans Wolff, François Chappuis and Laurent Getaz
Published on: 11 May 2016
Abstract
Background
Large numbers of Latin American immigrants recently arrived in Western Europe. Curative and preventive programmes need to take account of their risk of suffering and transmitting imported chronic infections and of their susceptibility to cosmopolitan infections. We aimed to assess the prevalence and co-occurrence of imported chronic infections among Latin American immigrants, and their susceptibility to highly prevalent cosmopolitan infections.
Methods
Adult participants were recruited in the community and in a primary health centre in Geneva in 2008. Serological tests were performed on stored sera for HIV, HBV, syphilis, Strongyloides stercoralis, Trypanosoma cruzi, varicella and measles. We considered only chronic active infections in the analysis.
Results and discussion
The 1 012 participants, aged 37.2 (SD 11.3) years, were mostly female (82.5 %) and Bolivians (48 %). Overall, 209 (20.7 %) had at least one and 27 (2.7 %) two or more chronic infections. T. cruzi (12.8 %) and S. stercoralis (8.4 %) were the most prevalent chronic active infections compared to syphilis (0.4 %), HBV (0.4 %) and HIV (1.4 %). Concomitant infections affected 28.2 and 18.5 % of T. cruzi and S. stercoralis infected cases. Bolivian origin (aOR: 13.6; 95 % CI: 3.2–57.9) was associated with risk of multiple infections. Susceptibilities for VZV and measles were 0.7 and 1.4 %, respectively. Latin American immigrants are at risk of complications and possible reactivation of chronic parasitic infections but have overall low risks of chronic viral and syphilitic active infections.
Conclusions
Systematic screening for chronic active parasitic infections is therefore necessary especially among Bolivians. The high protection rate against measles and VZV doesn’t require specific preventive interventions.

International Health – Volume 8 Issue 3 May 2016

International Health
Volume 8 Issue 3 May 2016
http://inthealth.oxfordjournals.org/content/current

.
EDITORIAL
Africa in transition: the case of malaria
Kevin Marsh
Extract
Int. Health (2016) 8 (3): 155-156 doi:10.1093/inthealth/ihw022
In 2000, the Economist carried an infamous cover describing Africa as ‘the hopeless continent’. In 2013 this was replaced with one designating Africa ‘the hopeful continent’. The idea of ‘Africa rising’ is in the air and although this is a hotly debated area, no one doubts that Africa is in a period of dramatic transition. Most African economies are growing at around 5% per annum; the current GDP of Africa of around $2.4 trillion is expected to rise more than tenfold by 2050, when its population is predicted to be above 2 billion, with 60% living in urban areas. These changes will be paralleled by equally dramatic changes in health, a process which is already well underway. Much has been written about the dual challenges of persisting infectious diseases at the same time as an increasing burden of non-communicable diseases. Tackling these challenges will call for a major investment in research and here there are exciting transitions too. The launch by the African Academy of Sciences (ASS), in-partnership with NEPAD and a group of international partners, of the Alliance for Accelerating Excellence in Science in Africa (AESA) (http://aasciences.ac.ke/programmes/easa/alliance-for-accelerating-excellence-in-science-in-africa-aesa/) marks a genuine shift in the centre of gravity for health research in Africa. One particularly welcome manifestation of this …

Taking forward the World TB Day 2016 theme ‘Unite to End Tuberculosis’ for the WHO Africa Region

International Journal of Infectious Diseases
May 2016 Volume 46, p1-126
http://www.ijidonline.com/current

.
Original Reports
Taking forward the World TB Day 2016 theme ‘Unite to End Tuberculosis’ for the WHO Africa Region
Francine Ntoumi, Pontiano Kaleebu, Eusebio Macete, Sayoki Mfinanga, Jeremiah Chakaya, Dorothy Yeboah-Manu, Matthew Bates, Peter Mwaba, Markus Maeurer, Eskild Petersen, Alimuddin Zumla
p34–37
Published online: March 8 2016
Preview
Tuberculosis (TB) has remained a global emergency ever since it was declared as such by the World Health Organization (WHO) in 1993.1 The theme designated for this year’s World TB Day, March 24, 2016, is ‘Unite to End TB’.2 World TB Day is held to commemorate the day in 1882 when Professor Robert Koch announced his ground-breaking discovery of the cause of TB, the bacillus Mycobacterium tuberculosis.3 At the time of Koch’s announcement in Berlin, TB was widespread and rampaging through Europe and the Americas, causing the death of one out of every seven people.

The Emerging Zika Virus Epidemic in the Americas: Research Priorities

JAMA
May 10, 2016, Vol 315, No. 18
http://jama.jamanetwork.com/issue.aspx

.
Viewpoint
The Emerging Zika Virus Epidemic in the Americas: Research Priorities FREE
Helen M. Lazear, PhD; Elizabeth M. Stringer, MD; Aravinda M. de Silva, PhD
Excerpt
…CONCLUSIONS
The size of the current ZIKV epidemic, its potential for further spread, and the potential teratogenic effects of this virus require development of ZIKV-specific diagnostic agents and a better understanding of pathogenic mechanisms. The association between ZIKV infection and microcephaly has been the cause of much alarm and has been the driving force behind a substantial public health response and a drive to develop vaccines and antivirals to combat ZIKV infection.
Zika virus represents just the most recent example of an epidemic of vector-borne disease brought about by the introduction of a virus to a new host population and ecological landscape. Although current research priorities must focus on the immediate need to develop specific diagnostic tools and understand the teratogenic potential of ZIKV, public health efforts to address the current epidemic must be informed by experience with previous outbreaks of viruses transmitted by Aedes mosquitoes.

JAMA Pediatrics – May 2016

JAMA Pediatrics
May 2016, Vol 170, No. 5
http://archpedi.jamanetwork.com/issue.aspx
.
Editorial
Adolescent and Young Adult Health
The Pertussis Problem and a Possible Solution: Will Parents Go Along?
Mark H. Sawyer, MD
.
Adolescent and Young Adult Health
Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females
Annika M. Hofstetter, MD, PhD, MPH; Danielle C. Ompad, PhD; Melissa S. Stockwell, MD, MPH; Susan L. Rosenthal, PhD; Karen Soren, MD
.
Adolescent and Young Adult Health
Impact of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccinations on Reported Pertussis Cases Among Those 11 to 18 Years of Age in an Era of Waning Pertussis Immunity: A Follow-up Analysis
Tami H. Skoff, MS; Stacey W. Martin, MSc
.
Epidemiological and Economic Effects of Priming With the Whole-Cell Bordetella pertussis Vaccine
Haedi DeAngelis, MA; Samuel V. Scarpino, PhD; Meagan C. Fitzpatrick, PhD; Alison P. Galvani, PhD; Benjamin M. Althouse, PhD, ScM
Includes: Supplemental Content

Journal of Epidemiology & Community Health – June 2016

Journal of Epidemiology & Community Health
June 2016, Volume 70, Issue 6
http://jech.bmj.com/content/current

.
Essay
Birth control policies in Iran: a public health and ethics perspective
Mehdi Aloosh1, Yashar Saghai2
Author Affiliations
1McGill University Health Centre, Montreal, Quebec, Canada
2Berman Institute of Bioethics, Johns Hopkins University, Baltimore, USA
Correspondence to Dr Mehdi Aloosh, McGill University, McGill University Health Centre, Montreal, Quebec, H4A 3J1, Canada; mehdi.aloosh@mail.mcgill.ca
Abstract
In less than one generation, a unique demographic transition has taken place in Iran. A population growth rate of 4.06% in 1984 fell to 1.15% in 1993 and a total fertility rate of 6.4 births per woman in 1984 declined to 1.9 in 2010. In 2012, Iranian policymakers shifted away from a birth control policy towards a pro-natalist policy. At first glance, this may seem reasonable since its goal is to avoid the consequences of an aging population. However, we argue that the policy package raises serious public health, socioeconomic, environmental and ethical concerns and is likely to fail on its own terms.

.

The influence of refugee status and secondary migration on preterm birth
Susitha Wanigaratne1,2, Donald C Cole3, Kate Bassil3, Ilene Hyman3, Rahim Moineddin4,
Marcelo L Urquia1,2,3
Author Affiliations
1Centre for Research on Inner City Health, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, Ontario, Canada
2Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
3Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
4Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada
Correspondence to Dr Marcelo L Urquia, St. Michael’s Hospital, 30 Bond St., Toronto, ON M5B 1W8, Canada; marcelo.urquia@utoronto.ca
Abstract
Background It is unknown whether the risk of preterm birth (PTB) is elevated for forced (refugee) international migrants and whether prolonged displacement amplifies risk. While voluntary migrants who arrive from a country other than their country of birth (ie, secondary migrants) have favourable birth outcomes compared with those who migrated directly from their country of birth (ie, primary migrants), secondary migration may be detrimental for refugees who experience distinct challenges in transition countries. Our objectives were (1) to determine whether refugee status was associated with PTB and (2) whether the relation between refugee status and PTB differed between secondary and primary migrants.
Methods We conducted a retrospective population-based cohort study. Ontario immigration (2002–2010) and hospitalisation data (2002–2010) were linked to estimate adjusted cumulative odds ratios (ACOR) of PTB (22–31, 32–36, 37–41 weeks of gestation), with 95% CIs (95% CI) comparing refugees with non-refugees. We further included a product term between refugee status and secondary migration.
Results Overall, refugees (N=12 913) had 17% greater cumulative odds of short gestation (ACOR=1.17, 95% CI 1.07 to 1.28) compared with non-refugees (N=110 640). Secondary migration modified the association between refugee status and PTB (p=0.007). Secondary refugees had 58% greater cumulative odds of short gestation (ACOR=1.58, 95% CI 1.25 to 2.00) than secondary non-refugees, while primary refugees had 12% greater cumulative odds of short gestation (ACOR=1.12, 95% CI 1.02 to 1.23) than primary non-refugee immigrants.
Conclusions Refugee status, jointly with secondary migration, influences PTB among migrants.

Journal of Pediatrics – May 2016

Journal of Pediatrics
May 2016 Volume 172, p1-236
http://www.jpeds.com/current

.
Editor’s Persepctive
Lest we forget — the battle against malnutrition
Carlos A. Cuello-Garcia
p1–4
Published in issue: May 2016
Preview
We are now living in an era of postmillennium development goals and, although a significant number of them have been completed, a significant proportion of targets remain to be accomplished. Malnutrition is still a concern that affects millions worldwide. In this issue of The Journal, Chowdhury et al present a large scale population-based survey in Bangladesh, extracted from the Bangladesh Demographic Health Survey (2011). This could be considered a large and representative sample of a region where prevention of malnutrition is (and it should be kept as) a priority as a public health intervention.

.
Original Articles
Risk Factors for Child Malnutrition in Bangladesh: A Multilevel Analysis of a Nationwide Population-Based Survey
Mohammad Rocky Khan Chowdhury, Mohammad Shafiur Rahman, Mohammad Mubarak Hossain Khan, Mohammad Nazrul Islam Mondal, Mohammad Mosiur Rahman, Baki Billah
p194–201.e1
Published online: February 5 2016

.
Original Articles
Sustained Effectiveness of Monovalent and Pentavalent Rotavirus Vaccines in Children
Lilly Cheng Immergluck, Trisha Chan Parker, Shabnam Jain, Elham Laghaie, Philip Spandorfer, Robert C. Jerris, Michael D. Bowen, Umesh D. Parashar, Margaret M. Cortese
p116–120.e1
Published online: February 27 2016
Abstract
Objective
Using case-control methodology, we measured the vaccine effectiveness (VE) of the 2-dose monovalent rotavirus vaccine (RV1) and 3-dose pentavalent rotavirus vaccine (RV5) series given in infancy against rotavirus disease resulting in hospital emergency department or inpatient care.
Study design
Children were eligible for enrollment if they presented to any 1 of 3 hospitals in Atlanta, Georgia with diarrhea ≤10 days duration during January-June 2013 and were born after RV1 introduction. Stool samples were tested for rotavirus by enzyme immunoassay and immunization records were obtained from providers and the state electronic immunization information system. Case-subjects (children testing rotavirus antigen-positive) were compared with children testing rotavirus antigen-negative.
Results
Overall, 98 rotavirus-case subjects and 175 rotavirus-negative controls were enrolled. Genotype G12P[8] predominated (n = 87, 89%). The VE of 2 RV1 doses was 84% (95% CI 38, 96) among children aged 8-23 months and 82% (95% CI 41, 95) among children aged ≥24 months. For the same age groups, the VE of 3 RV5 doses was 80% (95% CI 27, 95) and 87% (95% CI 22, 98), respectively.
Conclusions
Under routine use, the RV1 and RV5 series were both effective against moderate-to-severe rotavirus disease during a G12P[8] season, and both vaccines demonstrated sustained protection beyond the first 2 years of life.

Moving ahead: what will a renewed Countdown to 2030 for Women and Children look like?

The Lancet
May 14, 2016 Volume 387 Number 10032 p1969-2062
http://www.thelancet.com/journals/lancet/issue/current

.
Viewpoint
Moving ahead: what will a renewed Countdown to 2030 for Women and Children look like?
Prof Zulfiqar A Bhutta, PhD, Mickey Chopra, MD
Published Online: 15 October 2015
Summary
The Countdown to 2015 initiative (Countdown) represents a remarkable consortium of academicians, UN agencies, and development partners, which over the past decade, has focused its attention on tracking and analysing coverage of key interventions for reproductive, maternal, newborn, and child health (RMNCH) across 75 high burden countries that account for more than 95% of global maternal and child deaths. Initially started to ensure follow-up on the landmark Lancet Child Survival series,1,2 with innovative consolidation and presentation of coverage data on key interventions by country and regions,3 Countdown rapidly evolved with an expansion of its mandate to include reproductive and maternal health indicators across the continuum of care4 and more recently, analysis of nutrition trends and health policies.

The Lancet Infectious Diseases – May 2016

The Lancet Infectious Diseases
May 2016 Volume 16 Number 5 p507-618 e64-e81
http://www.thelancet.com/journals/laninf/issue/current
.
Editorial
Ebola PHEIC is over but emergency continues
The Lancet Infectious Diseases
Summary
On March 29, WHO Director-General Margaret Chan announced that the outbreak of Ebola virus disease in countries of west Africa was no longer a Public Health Emergency of International Concern (PHEIC). This decision was taken because, in the opinion of the International Health Regulations Emergency Committee on Ebola, the outbreak is no longer an extraordinary event, there is little risk of international spread, and affected countries have the capacity to rapidly respond to new cases. The Emergency Committee acknowledged that new clusters will continue to occur, but that they are happening at a decreasing frequency.
.
Comment
Managing the risks of vaccine hesitancy and refusals
Ève Dubé, Noni E MacDonald
Published Online: 04 February 2016
DOI: http://dx.doi.org/10.1016/S1473-3099(16)00028-1
Summary
In The Lancet Infectious Diseases, John Glasser and colleagues1 report the results of a spatially-stratified model to better understand the dynamics of disease outbreaks and the link with vaccine hesitancy and refusal. Using data for 39 132 children starting elementary school in San Diego County, CA, USA, in 2008 (2% of whom had a personal-belief exception to vaccines), the authors show the effect of heterogeneity on the reproduction numbers for measles, mumps, and rubella. Although the mean population immunities for measles, mumps, and rubella were similar to the population-immunity thresholds, modelling for non-random mixing (unvaccinated children tend to preferentially mix with other unvaccinated children) and heterogeneity caused the basic reproductive numbers to increase by 70%, meaning that an introduced infectious person could cause an outbreak.
.
Articles
Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial
Robert S Heyderman, Shabir A Madhi, Neil French, Clare Cutland, Bagrey Ngwira, Doris Kayambo, Robert Mboizi, Anthonet Koen, Lisa Jose, Morounfolu Olugbosi, Frederik Wittke, Karen Slobod, Peter M Dull
Open Access
Summary
Background
Neonates born to women infected with HIV are at increased risk for invasive group B streptococcus (GBS) disease. We aimed to compare safety and immunogenicity of trivalent glycoconjugate GBS vaccine in pregnant women with and without HIV in Malawi and South Africa.
Methods
In our non-randomised phase 2, open-label, multicentre study, we recruited pregnant women attending two antenatal clinics, one in Blantyre, Malawi, and one in Soweto, Johannesburg, South Africa. Participants were divided into three groups on the basis of their HIV infection status (no infection, infection and high CD4 cell count [>350 cells per μL], and infection and low CD4 cell count [>50 to ≤350 cells per μL]) and received a 5 μg dose of glycoconjugate GBS vaccine (serotypes Ia, Ib, and III, with CRM197 [Novartis Vaccines, Siena, Italy]) intramuscularly at 24–35 weeks’ gestation. GBS serotype-specific antibody concentrations were measured before vaccination (day 1), day 15, day 31, and at delivery, and in infants at birth and day 42 of life. The primary outcomes were safety in mothers and infants and the amount of placental transfer of GBS serotype-specific antibodies from mothers to their infants. All immunogenicity and safety analyses were done on the full analysis set, including participants who, or whose mother, correctly received the vaccine and who provided at least one valid assessable serum sample. This study is registered with ClinicalTrials.gov, number NCT01412801.
Findings
270 women and 266 infants were enrolled between Sept 26, 2011, and Dec 4, 2012 (90 women and 87 infants without HIV, 89 and 88 with HIV and high CD4 cell counts, and 91 and 91 with HIV and low CD4 cell counts, respectively). Seven women were lost to follow-up, six withdrew consent, one died, and two relocated. Eight infants died or were stillborn and two were lost to follow-up. Across serotypes, fold change in antibody concentrations were higher for the HIV-uninfected group than the HIV-infected groups. Transfer ratios were similar across all three groups (0·49–0·72; transfer ratio is infant geometric mean antibody concentration in blood collected within 72 h of birth divided by maternal geometric mean antibody concentration in blood collected at delivery); however, at birth, maternally derived serotype-specific antibody concentrations were lower for infants born to women infected with HIV (0·52–1·62 μg/mL) than for those born to women not infected with HIV (2·67–3·91 μg/mL). 151 (57%) of 265 women reported at least one solicited adverse reaction: 39 (45%) of 87 women with HIV and low CD4 cell counts, 52 (59%) of 88 women with HIV and high CD4 cell counts, and 60 (67%) of 90 women in the HIV-uninfected group. 49 (18%) of 269 women had at least one adverse event deemed possibly related to the vaccine (six [7%] in the HIV and low CD4 cell count group, 12 [13%] in the HIV and high CD4 cell count group, and 21 [23%] in the HIV-uninfected group), as did three (1%) of 266 neonates (zero, two [1%], and one [1%]); none of these events was regarded as serious.
Interpretation
The vaccine was less immunogenic in women infected with HIV than it was in those not infected, irrespective of CD4 cell count, resulting in lower levels of serotype-specific maternal antibody transferred to infants, which could reduce vaccine protection against invasive GBS disease. A validated assay and correlate of protection is needed to understand the potential protective value of this vaccine.
Funding
Novartis Vaccines and Diagnostics division (now part of the GlaxoSmithKline group of companies), Wellcome Trust UK, Medical Research Council: Respiratory and Meningeal Pathogens Research Unit
.
Articles
Effect of vaccination programmes on mortality burden among children and young adults in the Netherlands during the 20th century: a historical analysis
Maarten van Wijhe, Scott A McDonald, Hester E de Melker, Maarten J Postma, Jacco Wallinga
Summary
Background
In the 20th century, childhood mortality decreased rapidly, and vaccination programmes are frequently suggested as a contributing factor. However, quantification of this contribution is subject to debate or absent. We present historical data from the Netherlands that allow us to quantify the reduction in childhood mortality burden for vaccine-preventable diseases in this period as a function of vaccination coverage.
Methods
We retrieved cause-specific and age-specific historical mortality data from Statistics Netherlands from 1903 to 2012 (for Dutch birth cohorts born from 1903 to 1992), and data for vaccination coverage since the start of vaccination programmes from the Dutch Health Care Inspectorate and the Dutch National Institute for Public Health and the Environment. We also obtained birth and migration data from Statistics Netherlands. We used a restricted mean life-time method to estimate cause-specific mortality burden among children and young adults for each birth cohort as the years of life lost up to age 20 years, excluding migration as a variable because this did not affect the results. To correct for long-term trends, we calculated the cause-specific contribution to the total childhood mortality burden.
Findings
In the prevaccination era, the contribution to mortality burden was fairly constant for diphtheria (1·4%), pertussis (3·8%), and tetanus (0·1%). Around the start of mass vaccinations, these contributions to the mortality burden decreased rapidly to near zero. We noted similar patterns for poliomyelitis, mumps, and rubella. The number of deaths due to measles around the start of vaccination in the Netherlands were too few to detect an accelerated rate of decrease after mass vaccinations were started. We estimate that mass vaccination programmes averted 148 000 years of life lost up to age 20 years (95% prediction interval 110 000–201 000) among children born before 1992. This corresponds to about 9000 deaths averted (6000–12 000).
Interpretation
Our historical time series analysis of mortality and vaccination coverage shows a strong association between increasing vaccination coverage and diminishing contribution of vaccine-preventable diseases to overall mortality. This analysis provides further evidence that mass vaccination programmes contributed to lowering childhood mortality burden.
Funding
Dutch Ministry of Health, Welfare and Sport.
.
Articles
The effect of heterogeneity in uptake of the measles, mumps, and rubella vaccine on the potential for outbreaks of measles: a modelling study
John W Glasser, Zhilan Feng, Saad B Omer, Philip J Smith, Lance E Rodewald
Summary
Background
Vaccination programmes to prevent outbreaks after introductions of infectious people aim to maintain the average number of secondary infections per infectious person at one or less. We aimed to assess heterogeneity in vaccine uptake and other characteristics that, together with non-random mixing, could increase this number and to evaluate strategies that could mitigate their impact.
Methods
Because most US children attend elementary school in their own neighbourhoods, surveys of children entering elementary school (age 5 years before Sept 1) allow assessment of spatial heterogeneity in the proportion of children immune to vaccine-preventable diseases. We used data from a 2008 school-entry survey by the Immunization Division of the California Department of Public Health to obtain school addresses; numbers of students enrolled; proportions of enrolled students who had received one or two doses of the measles, mumps, and rubella (MMR) vaccine; and proportions with medical or personal-belief exemptions. Using a mixing model suitable for spatially-stratified populations, we projected the expected numbers of secondary infections per infectious person for measles, mumps, and rubella. We also mapped contributions to this number for measles in San Diego County’s 638 elementary schools and its largest district, comprising 200 schools (31%). We then modelled the effect on measles’ realised reproduction number (RV) of the following plausible interventions: vaccinating all children with personal-belief exemptions, increasing uptake by 10% to 50% in all low-immunity schools (<90% of students immune) or in only influential (effective daily contact rates >3 or contacts inter-school >30%) low-immunity schools, and increasing private school uptake to the public school average.
Findings
In 2008, 39 132 children began elementary school in San Diego County, CA, USA. At entry to school, 97% had received at least one dose of the MMR vaccine, with 2·5% having personal-belief exemptions. We note substantial heterogeneity in immunity throughout the county. Although the average population immunities for measles, mumps, and rubella (92%, 87%, 92%) were similar to the population-immunity thresholds in homogeneous, randomly-mixing populations (91%, 88%, 76%), after accounting for heterogeneity and non-random mixing, the basic reproduction numbers increased by 70%, meaning that introduced pathogens could cause outbreaks. The impact of our modelled interventions ranged from negligible to a nearly complete reduction in the outbreak potential of measles. The most effective intervention to lower the realised reproduction number (RV 3·39) was raising immunity by 50% in 114 schools with low immunity (RV 1·02), but raising immunity by this level in only influential, low-immunity schools also was effective (RV 2·02). The effectiveness of vaccinating the 972 children with personal-belief exemptions was similar to that of targeting all low-immunity schools (RV 1·11). Targeting only private schools had little effect.
Interpretation
Our findings suggest that increasing vaccine uptake could prevent outbreaks such as that of measles in San Diego in 2008. Vaccinating children with personal-belief exemptions was one of the most effective interventions that we modelled, but further research on mixing in heterogeneous populations is needed.
Funding
None.

Lancet Global Health – May 2016

Lancet Global Health
May 2016 Volume 4 Number 5 e287-e343
http://www.thelancet.com/journals/langlo/issue/current

.
Editorial
Research capacity in Africa—will the sun rise again?
Justine Davies, Zoë Mullan
Published Online: 31 March 2016
Open Access
DOI: http://dx.doi.org/10.1016/S2214-109X(16)30046-8
Summary
Africa has a problem. It has the greatest burden of disease and lowest density of health-care professionals in the world. This we know. We also know that although infectious diseases and maternal, child, and neonatal health are improving, the burden of non-communicable diseases (NCDs) has been steadily increasing in the past few decades. We know that the health-care successes in Africa have largely been driven by donor aid, providing vertical solutions to specific problems; however, NCDs require complex care and strong health systems.

.
Comment
How the MDGs gave up on measuring access to medicines
Dzintars Gotham, Kristine H Onarheim, Melissa J Barber
Open Access
DOI: http://dx.doi.org/10.1016/S2214-109X(16)00066-8
Summary
In March, 2016, the United Nations Statistics Commission agreed upon the metrics used to measure progress towards, or away from, the new Sustainable Development Goals (SDGs).1 These so-called indicators define the real-world, measurable counterparts to the targets within the visionary goals of the sustainable development agenda. In the context of health in the SDGs, we wish to highlight the little-known story of the Millennium Development Goals’ (MDG) target on access to medicines. Of the 21 targets in the eight MDGs that permeated the development debate over the past 15 years, it was the only target that was dropped from the MDG report.

The Zika Challenge

New England Journal of Medicine
May 12, 2016 Vol. 374 No. 19
http://www.nejm.org/toc/nejm/medical-journal

.
Perspective
The Zika Challenge
C.J. Haug, M.P. Kieny, and B. Murgue
[Concluding text]
…Many lessons learned from the response to the recent Ebola outbreak have helped in the response to the ZIKV outbreak. Most important, there is general agreement on the need for international collaboration on regulatory issues, research, and data sharing. For example, major regulatory agencies (such as Brazil’s Agência Nacional de Vigilância Sanitária, the U.S. Food and Drug Administration, and the European Medicines Agency) have committed to prioritizing the expedited evaluation of Zika products and will proactively reach out to product developers to provide advice on regulatory issues. Regulators have also initiated collaborations and are sharing their experiences with each other.

Another major advance over the Ebola response has been the speed with which data are being shared — for example, through the real-time posting of data from pathogenesis experiments in nonhuman primates. The December 2015 statement from the International Committee of Medical Journal Editors clarifying that prepublication dissemination of critical information will not prejudice later journal publication related to ZIKV or future public health emergencies has been helpful. Similarly, a February 2016 statement on open data sharing in ZIKV has been transformative in signaling that funders expect proactive data sharing. ZIKV provides a case study of the need for expedited research to answer basic questions, which will allow for development of control measures.

We are working in a new area with many unknowns. But as the WHO meeting showed, there is ample experience and expertise from work with other viruses and vectors — ranging from basic science to field work and surveillance — to guide clinical practice, research, and product development. It is critical that we collaborate rather than compete to find answers to the questions that worry millions of women of child-bearing age in areas where ZIKV is spreading rapidly and may become endemic.

Socioeconomic Inequalities in Neglected Tropical Diseases: A Systematic Review

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 14 May 2016)

.
Review
Socioeconomic Inequalities in Neglected Tropical Diseases: A Systematic Review
Tanja A. J. Houweling, Henrike E. Karim-Kos, Margarete C. Kulik, Wilma A. Stolk, Juanita A. Haagsma, Edeltraud J. Lenk, Jan Hendrik Richardus, Sake J. de Vlas
| published 12 May 2016 | PLOS Neglected Tropical Diseases
http://dx.doi.org/10.1371/journal.pntd.0004546
Abstract
Background
Neglected tropical diseases (NTDs) are generally assumed to be concentrated in poor populations, but evidence on this remains scattered. We describe within-country socioeconomic inequalities in nine NTDs listed in the London Declaration for intensified control and/or elimination: lymphatic filariasis (LF), onchocerciasis, schistosomiasis, soil-transmitted helminthiasis (STH), trachoma, Chagas’ disease, human African trypanosomiasis (HAT), leprosy, and visceral leishmaniasis (VL).
Methodology
We conducted a systematic literature review, including publications between 2004–2013 found in Embase, Medline (OvidSP), Cochrane Central, Web of Science, Popline, Lilacs, and Scielo. We included publications in international peer-reviewed journals on studies concerning the top 20 countries in terms of the burden of the NTD under study.
Principal findings
We identified 5,516 publications, of which 93 met the inclusion criteria. Of these, 59 papers reported substantial and statistically significant socioeconomic inequalities in NTD distribution, with higher odds of infection or disease among poor and less-educated people compared with better-off groups. The findings were mixed in 23 studies, and 11 studies showed no substantial or statistically significant inequality. Most information was available for STH, VL, schistosomiasis, and, to a lesser extent, for trachoma. For the other NTDs, evidence on their socioeconomic distribution was scarce.
The magnitude of inequality varied, but often, the odds of infection or disease were twice as high among socioeconomically disadvantaged groups compared with better-off strata. Inequalities often took the form of a gradient, with higher odds of infection or disease each step down the socioeconomic hierarchy. Notwithstanding these inequalities, the prevalence of some NTDs was sometimes also high among better-off groups in some highly endemic areas.
Conclusions
While recent evidence on socioeconomic inequalities is scarce for most individual NTDs, for some, there is considerable evidence of substantially higher odds of infection or disease among socioeconomically disadvantaged groups. NTD control activities as proposed in the London Declaration, when set up in a way that they reach the most in need, will benefit the poorest populations in poor countries.

Population-Level Impact of Ontario’s Infant Rotavirus Immunization Program: Evidence of Direct and Indirect Effects

PLoS One
http://www.plosone.org/
[Accessed 14 May 2016]

.
Research Article
Population-Level Impact of Ontario’s Infant Rotavirus Immunization Program: Evidence of Direct and Indirect Effects
Sarah E. Wilson, Laura C. Rosella, Jun Wang, Nicole Le Saux, Natasha S. Crowcroft, Tara Harris, Shelly Bolotin, Shelley L. Deeks
| published 11 May 2016 | PLOS ONE
http://dx.doi.org/10.1371/journal.pone.0154340
Abstract
Objective
To evaluate the direct and indirect population impact of rotavirus (RV) immunization on hospitalizations and emergency department (ED) visits for acute gastroenteritis (AGE) in Ontario before and after the publicly-funded RV immunization program.
Methods
Administrative data was used to identify ED visits and hospitalizations for all Ontarians using ICD-10 codes. We used two outcome definitions: RV-specific AGE (RV-AGE) and codes representing RV-, other viral and cause unspecified AGE (“overall AGE”). The pre-program and public program periods were August 1, 2005 to July 31, 2011; and August 1, 2011 to March 31, 2013, respectively. A negative binominal regression model that included the effect of time was used to calculate rates and rate ratios (RRs) and 95% confidence intervals (CIs) for RV-AGE and overall AGE between periods, after adjusting for age, seasonality and secular trends. Analyses were conducted for all ages combined and age stratified.
Results
Relative to the pre-program period, the adjusted RRs for RV-AGE and overall AGE hospitalizations in the public program period were 0.29 (95%CI: 0.22–0.39) and 0.68 (95%CI: 0.62–0.75), respectively. Significant reductions in RV-AGE hospitalizations were noted overall and for the following age bands: < 12 months, 12–23 months, 24–35 months, 3–4 years, and 5–19 years. Significant declines in overall AGE hospitalizations were observed across all age bands, including older adults > = 65 years (RR 0.80, 95%CI: 0.72–0.90). The program was associated with adjusted RRs of 0.32 (95% CI: 0.20–0.52) for RV-AGE ED visits and 0.90 (95% CI: 0.85–0.96) for overall AGE ED visits.
Conclusions
This large, population-based study provides evidence of the impact of RV vaccine in preventing hospitalizations and ED visits for RV-AGE and overall AGE, including herd effects.

Science – 13 May 2016

Science
13 May 2016 Vol 352, Issue 6287
http://www.sciencemag.org/current.dtl

.
Zika virus impairs growth in human neurospheres and brain organoids
By Patricia P. Garcez, Erick Correia Loiola, Rodrigo Madeiro da Costa, Luiza M. Higa, Pablo Trindade, Rodrigo Delvecchio, Juliana Minardi Nascimento, Rodrigo Brindeiro, Amilcar Tanuri, Stevens K. Rehen
Science13 May 2016 : 816-818
Zika virus infection in cell culture models damages human neural stem cells to limit growth and cause cell death.

The need for global regulatory harmonization: A public health imperative

Science Translational Medicine
11 May 2016 Vol 8, Issue 338
http://stm.sciencemag.org/

.
Editorial
The need for global regulatory harmonization: A public health imperative
By Elias Zerhouni, Margaret Hamburg
Science Translational Medicine11 May 2016 : 338ed6
Because public health and innovation are no longer national issues, regulatory authorities must apply a global view to oversight.

Global health diplomacy: A critical review of the literature

Social Science & Medicine
Volume 155, Pages 1-102 (April 2016)
http://www.sciencedirect.com/science/journal/02779536/155

.
Review article
Global health diplomacy: A critical review of the literature
Review Article
Pages 61-72
Arne Ruckert, Ronald Labonté, Raphael Lencucha, Vivien Runnels, Michelle Gagnon
Abstract
Global health diplomacy (GHD) describes the practices by which governments and non-state actors attempt to coordinate and orchestrate global policy solutions to improve global health. As an emerging field of practice, there is little academic work that has comprehensively examined and synthesized the theorization of Global Health Diplomacy (GHD), nor looked at why specific health concerns enter into foreign policy discussion and agendas. With the objective of uncovering the driving forces behind and theoretical explanations of GHD, we conducted a critical literature review. We searched three English-language scholarly databases using standardized search terms which yielded 606 articles. After screening of abstracts based on our inclusion/exclusion criteria, we retained 135 articles for importing into NVivo10 and coding. We found a lack of rigorous theorizing about GHD and fragmentation of the GHD literature which is not clearly structured around key issues and their theoretical explanations. To address this lack of theoretical grounding, we link the findings from the GHD literature to how theoretical concepts used in International Relations (IR) have been, and could be invoked in explaining GHD more effectively. To do this, we develop a theoretical taxonomy to explain GHD outcomes based on a popular categorization in IR, identifying three levels of analysis (individual, domestic/national, and global/international) and the driving forces for the integration of health into foreign policy at each level.

Factors associated with incomplete or delayed vaccination across countries: A systematic review

Vaccine
Volume 34, Issue 24, Pages 2635-2758 (23 May 2016)
http://www.sciencedirect.com/science/journal/0264410X/34/24
.

Review
Factors associated with incomplete or delayed vaccination across countries: A systematic review
Review Article
Pages 2635-2643
Márcia de Cantuária Tauil, Ana Paula Sayuri Sato, Eliseu Alves Waldman
Abstract
Background
Despite the significant decline in the incidence of vaccine-preventable diseases as a result of increased vaccination coverage worldwide, there are many children with delayed vaccination and a marked heterogeneity in vaccination coverage.
Objective
The aim of this study was to review factors that influence the adherence to childhood immunization schedule in different countries, especially related to socioeconomic conditions and health care system characteristics.
Methods
Pubmed and Web of Science databases were searched systematically for observational studies published in peer-reviewed journals in English, Spanish and Portuguese languages from January 1992 to June 2014. We included original articles that assessed vaccination schedule with at least three diphtheria–tetanus–pertussis, three polio and one measles vaccines in children aged 0–24 months.
Results
491 articles were identified and 23 met the inclusion criteria and were reviewed. The most cited factors reported by countries with distinct characteristics were higher birth order (9 articles, 39.1%), and low maternal education/socioeconomic status (7 articles each one, 30.4%). Irregular monitoring by the health care services was reported by countries with “mainly private” health care system. Out-of-hospital birth, no reminder(s) about the next follow-up visit, and mother working outside the home were cited by countries with low/medium Human Development Index (HDI). Ethnicity, use of private health care services, and no health insurance were cited by countries with very high HDI. The role of migration on vaccination coverage was reported by three studies conducted in countries with distinct characteristics.
Conclusions
The factors are complex and driven by context. Overall, strengthening the contacts and relationships between the health care services and mothers with several children and families with low educational level/low socioeconomic status appear to be an important action to improve vaccination coverage.

Establishing herd immunity against Ebola through vaccination

Vaccine
Volume 34, Issue 24, Pages 2635-2758 (23 May 2016)
http://www.sciencedirect.com/science/journal/0264410X/34/24
.
Regular papers
Establishing herd immunity against Ebola through vaccination
Original Research Article
Pages 2644-2647
Kimberly Gittings, Kelly L. Matson
Abstract
Objectives
In response to recent concern regarding Ebola outbreaks, this study aims to (1) determine the relationship between vaccination coverage and herd immunity, (2) determine the vaccination coverage necessary to establish herd immunity for previous Ebola viruses, and (3) recommend vaccination coverage thresholds for future Ebola viruses.
Methods
Herd immunity thresholds needed to block transmission of Ebola virus were determined using vaccine efficacy and number of secondary cases per infected case during an entire infectious period.
Results
In past Ebola outbreaks 42.2–63.0% of the population would need to be vaccinated in order to prevent transmission and outbreaks. Assuming 80% vaccine efficacy as reported by phase I clinical trials, 52.7–78.7% of the population would require vaccination coverage in order to establish herd immunity. In recent ring vaccination trials which considered the vaccine to be 100% effective after 10 days, 42.2–63.0% of the population would need to be vaccinated.
Conclusion
For future Ebola outbreaks, the spread of the virus can be prevented by vaccinating certain percentages of the population depending on vaccine efficacy and number of secondary cases per infected case.

Effect of introduction of pentavalent vaccine as replacement for Diphtheria–Tetanus–Pertussis and Hepatitis B vaccines on vaccination uptake in a health facility in Nigeria

Vaccine
Volume 34, Issue 24, Pages 2635-2758 (23 May 2016)
http://www.sciencedirect.com/science/journal/0264410X/34/24
.
Effect of introduction of pentavalent vaccine as replacement for Diphtheria–Tetanus–Pertussis and Hepatitis B vaccines on vaccination uptake in a health facility in Nigeria
Original Research Article
Pages 2722-2728
Ayebo Evawere Sadoh, Damian Uchechukwu Nwaneri, Bamidele Charity Ogboghodo, Wilson Ehidiamen Sadoh
Abstract
Background
The introduction of a new vaccine into an immunization programme may affect the immunization system negatively or positively. The aim of this study is to determine the effect of the introduction of the pentavalent vaccine as replacement for DTP and Hepatitis B vaccines on timeliness, completion of the schedule and dropout rates among children attending a health facility.
Methodology
This was a retrospective cohort study which involved extracting immunization records of children attending the Institute of Child Health Child Welfare Clinic between June 2011 and May 2013. Pentavalent vaccine was introduced as a replacement for DTP and Hepatitis B vaccines in June 2012. The uptake, timeliness and dropout rates of different vaccines in the immunization schedule were determined for children who commenced immunization in the pre, peri and post introduction phases.
Results
A total of 1110 children were studied – 190, 410 and 510 who commenced vaccination in the pre, peri and post introduction phases of the pentavalent vaccine respectively. Uptake was significantly higher for all vaccines in the post introduction phase compared to pre and peri introduction phases (p < 0.001). Completion of the immunization schedule by 60.2% of the children who commenced vaccination in the post introduction phase was higher than the 31.6% and 41.7% for the pre and peri introduction phases respectively (p < 0.001). Significantly more visits were required to complete the schedule in the peri introduction phase compared to the pre and post introduction phases p < 0.001. Delay in receipt of the three doses of DTP/PENTA was significantly longer in the peri introduction phase compared to pre and post introduction phases.
Conclusion
The introduction of pentavalent vaccine significantly improved uptake of vaccines and completion of the schedule but resulted in prolonged delay in receipt of vaccines during the introduction period.

Critical role of ethics in clinical management and public health response to the West Africa Ebola epidemic

Risk Management and Healthcare Policy
Volume 9

Review
Critical role of ethics in clinical management and public health response to the West Africa Ebola epidemic
Morenike O Folayan1,2 Bridget G Haire3 Brandon Brown4
1Institute of Public Health, 2Department of Child Dental Health, Obafemi Awolowo University, Ile-Ife, Nigeria; 3Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, NSW, Australia; 4Center for Healthy Communities, Department of Social Medicine and Population Health, University of California Riverside School of Medicine, Riverside, CA, USA
Abstract:
The devastation caused by the Ebola virus disease (EVD) outbreak in West Africa has brought to the fore a number of important ethical debates about how best to respond to a health crisis. These debates include issues related to prevention and containment, management of the health care workforce, clinical care, and research design, all of which are situated within the overarching moral problem of severe transnational disadvantage, which has very real and specific impacts upon the ability of citizens of EVD-affected countries to respond to a disease outbreak. Ethical issues related to prevention and containment include the appropriateness and scope of quarantine and isolation within and outside affected countries. The possibility of infection in health care workers impelled consideration of whether there is an obligation to provide health services where personal protection equipment is inadequate, alongside the issue of whether the health care workforce should have special access to experimental treatment and care interventions under development. In clinical care, ethical issues include the standards of care owed to people who comply with quarantine and isolation restrictions. Ethical issues in research include appropriate study design related to experimental vaccines and treatment interventions, and the sharing of data and biospecimens between research groups. The compassionate use of experimental drugs intersects both with research ethics and clinical care. The role of developed countries also came under scrutiny, and we concluded that developed countries have an obligation to contribute to the containment of EVD infection by contributing to the strengthening of local health care systems and infrastructure in an effort to provide fair benefits to communities engaged in research, ensuring that affected countries have ready and affordable access to any therapeutic or preventative interventions developed, and supporting affected countries on their way to recovery from the impact of EVD on their social and economic lives.

Vaccines and Global Health: The Week in Review 7 May 2016

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

pdf version A pdf of the current issue is available here:  Vaccines and Global Health_The Week in Review_7 May 2016

blog edition: comprised of the approx. 35+ entries posted below on 10 May 2016.

Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy
a program of the
– Division of Medical Ethics, NYU Medical School
– Children’s Hospital of Philadelphia Vaccine Education Center
Associate Faculty, Division of Medical Ethics, NYU School of Medicine

Policy statement on data sharing by WHO in the context of public health emergencies

Policy statement on data sharing by WHO in the context of public health emergencies
(as of 13 April 2016)
Weekly Epidemiological Record (WER) 6 May 2016, vol. 91, 18 (pp. 237)

The primary purpose of data sharing by WHO during a public health emergency is to permit analyses that allow the fullest possible understanding of the emergency, and to ensure that decisions are based on the best available evidence.

There are different considerations for data sharing in public health emergencies in each of the following 3 categories: (1) surveillance, epidemiology and emer¬gency response, including health facilities, (2) genetic sequences, and (3) observa¬tional studies and clinical trials. This policy statement sets out to clarify WHO’s position in providing access to data in these 3 categories.

This statement does not cover other kinds of data that could be useful but which are not typically provided to WHO, such as telephone call detail records (CDR). Furthermore, this statement refers to the sharing of data only, not biological samples. The latter require a different set of considerations.

.
1. Surveillance, epidemiology and emergency response
It was recognized at the WHO R&D Blue¬print consultation in September 20151 that epidemiologic data belong to the coun¬tries in which they are generated. However, there was also consensus that data should be shared by default, but with an opt-out policy, to ensure that the knowledge gener¬ated becomes a global public good.

Articles 6–11 of the International Health Regulations (IHR) 2005 are intended to encourage States Parties to share information with WHO before a public health emergency of international concern (PHEIC) is declared. The restrictions on when WHO can disclose that infor¬mation publicly are in paragraph 4 of Article 11. Data can be made publicly available when both of the follow¬ing apply:

(1) the requirements for making the information avail¬able to States Parties are fulfilled, i.e. when (a) a PHEIC is declared or, (b) evidence indicates that there is, or will be, international spread of infections or other harmful agents or, (c) there is immediate need for inter¬national control measures, and
(2) other information about the event has already become publicly available and there is a need for the dissemination of authoritative information. In practical terms, this second requirement (information on the event is already public) is fulfilled in the earliest stages of an event, which permits disclosure to the public immediately following disclosure to States Parties.

Policy statement
Against this background, WHO makes the following the policy statement:
“In accordance with Article 11 of the IHR (2005), WHO will disclose and publish information received under Part II of the IHR (Information and Public Health Response), when requirements for disclosure (paragraphs 2 and 4 of Article 11) are satisfied [i.e. under conditions (a)-(c) above]. Data will be anonymized to protect privacy and to ensure confidentiality. WHO will consult with affected countries to inform them prior to disclos¬ing data. WHO underlines that countries should share benefits arising out of the utilization of the data received through WHO with the originating country in accor¬dance with applicable international commitments.”

This data includes data from surveillance and monitor¬ing (informing epidemiology), from the emergency response (e.g. contact tracing, vaccination, treatment), and data concerning health facilities (e.g. the numbers and locations of in-patient and out-patient centres, and the staff and medical facilities available at these centres).

Anonymization will remove all personal identifiers and locators, and will comply with personal data protection requirements as laid out in Article 45 of the IHR. Efforts will be made to curate data to increase their utility, and further analysis and reporting of new data generated will be encouraged. In exceptional cases, where there is a compelling reason to opt out of sharing subsets of data, this will be possible.

.
2. Genetic sequence data / information
The sharing of genetic sequence data / information is as important as the sharing of other event-related information in the IHR and restated above. Sharing data allows the better tracking of epidemics, and aids the development of diagnostic tests, therapeutics and vaccines.

It may be desirable to establish one or more consortia of public sector genome sequencers, who will provide a service to WHO in the context of a public health emer¬gency.

Policy statement
WHO will advocate that pathogen genome sequences be made publicly available as rapidly as possible through relevant databases and that benefits arising out of the utilization of those sequences be shared equitably with the country from where the pathogen genome sequence originates. This refers only to the public sharing of sequences, not to biological samples, which will be subject to a separate WHO policy (in preparation).

.
3. Observational studies and clinical trials
Observational and clinical studies relate to data gener¬ated under research protocols. For scientific reasons, these protocols often preclude the disclosure of data before predefined interim or final assessments. Further¬more, the early sharing of primary data generated in these studies in emergencies is not important in the same way that it is for epidemiological and genetic sequence data. The critical need in emergencies is to ensure that there is transparency about which studies and trials are being carried out, to specify in advance the points at which preliminary findings will be made available, and to work with researchers, funders and journals to make preliminary and final results available without delay.

Policy statement
All interventional clinical trials must be prospectively registered in a primary clinical trials registry, conform¬ing to standards agreed by WHO International Clinical Trials Registry Platform.2

During a public health emergency, each research proto¬col should make a specific commitment to share results in a pre-specified, expedited timeline before each trial begins. WHO’s position will be that the public disclo¬sure of results will be the norm, in the expedited time¬line as dictated by the research protocol. Outside public health emergencies the norm is for public disclosure of results within 12 months of completion of a trial.3

Transparency concerning the conduct of animal exper¬iments is important for drug and vaccine development. WHO will communicate the importance of transparency and a public log of all animal models with key outcomes should be maintained and updated.
.

Security of data held at WHO
WHO has a formal and comprehensive policy for securely managing all data bases and information sources hosted by the organization. The policy includes information security, technical and physical data secu¬rity, data access and retention procedures, and confiden¬tiality arrangements. As international civil servants, all WHO staff are required to adhere to the policy and its procedures (detailed under the staff regulations), including with full respect to Article 45 of the IHR (2005).

1 See http://www.who.int/medicines/ebola-treatment/data-sharing_phe/en/
2 See http://who.int/ictrp/en/
3 The WHO position is outlined at http://www.who.int/ictrp/results/reporting.

Zika virus [to 7 May 2016]

Zika virus [to 7 May 2016]
Public Health Emergency of International Concern (PHEIC)
http://www.who.int/emergencies/zika-virus/en/

.
Zika situation report – 5 May 2016
Zika virus, Microcephaly and Guillain-Barré syndrome
Read the full situation report
.
Summary
:: Mosquito-borne transmission:
…44 countries are experiencing a first outbreak of Zika virus since 2015, with no previous evidence of circulation, and with ongoing transmission by mosquitoes.
…13 countries reported evidence of Zika virus transmission between 2007 and 2014, with ongoing transmission.
…Four countries or territories have reported an outbreak since 2015 that is now over: Cook Islands, French Polynesia, ISLA DE PASCUA – Chile and YAP (Federated States of Micronesia).

:: Person-to-person transmission:
…Nine countries have reported evidence of person-to-person transmission of Zika virus, probably via a sexual route.

:: In the week to 4 May 2016, Peru and Saint Barthélemy are the latest country and territory to report mosquito-borne Zika virus transmission.

:: Microcephaly and other fetal malformations potentially associated with Zika virus infection or suggestive of congenital infection have been reported in six countries or territories. Two cases, each linked to a stay in Brazil, were detected in Slovenia and the United States of America. One additional case, linked to a brief stay in Mexico, Guatemala and Belize, was detected in a pregnant woman in the United States of America. A case in Marshall Islands was also recently reported and is awaiting confirmation.

:: In the context of Zika virus circulation, 13 countries and territories worldwide have reported an increased incidence of Guillain-Barré syndrome (GBS) and/or laboratory confirmation of a Zika virus infection among GBS cases.

:: Based on research to date, there is scientific consensus that Zika virus is a cause of microcephaly and GBS.

:: The global prevention and control strategy launched by the World Health Organization (WHO) as a Strategic Response Framework encompasses surveillance, response activities and research. Key interventions are being undertaken jointly by WHO and international, regional and national partners in response to this public health emergency.

:: Incident managers from the six WHO Regional Offices and headquarters, as well as relevant technical and support staff, are meeting in Washington D.C., USA on 4 and 5 May 2016 to review past and ongoing activities, to discuss key lessons and to develop a strategy for future action to ensure that the response collaboration continues to work effectively.

:: WHO has developed new advice and information on diverse topics in the context of Zika virus. WHO’s latest information materials, news and resources to support risk communication, and community engagement are available online.

.
WHO: One year into the Zika outbreak
5 May 2015 — On 7 May 2015, Brazil informed WHO/PAHO of its first laboratory confirmed cases of Zika virus. In the last year the scientific community has learned an extraordinary amount about this virus and its effects. WHO continues to lead the research agenda, while supporting countries in the response. This article chronicles Zika virus from when it was first identified, and details how this fairly obscure disease became a global health emergency.

.
Zika digital timeline
5 May 2016

.
Zika Open [to 7 May 2016]
[Bulletin of the World Health Organization]
:: All papers available here
New papers below:
Transmission of Zika virus through breast milk and other breastfeeding-related bodily-fluids: a systematic review
– Susannah Colt, Maria N Garcia-Casal, Juan Pablo Peña-Rosas, Julia L. Finkelstein, Pura Rayco-Solon, Zita Weise Prinzo, & Saurabh Mehta
Posted: 2 May 2016
http://dx.doi.org/10.2471/BLT.16.176677

.
CDC/ACIP [to 7 May 2016]
http://www.cdc.gov/media/index.html
THURSDAY, MAY 5, 2016
CDC adds Peru to interim travel guidance related to Zika virus
Today, CDC posted a Zika virus travel notice for Peru. CDC has issued travel notices (level 2, “practice enhanced precautions”) for people traveling to destinations with Zika.

MMWR May 6, 2016 / Vol. 65 / No. 17
:: Update: Ongoing Zika Virus Transmission — Puerto Rico, November 1, 2015–April 14, 2016

.
United Nations Zika Response Multi-Partner Trust Fund Launched
6 May 2016
SG/2228
United Nations Secretary-General Ban Ki-moon has established the United Nations Zika Response Multi-Partner Trust Fund to finance critical unfunded priorities in the response to the Zika outbreak. The Trust Fund provides a rapid, flexible and accountable platform to support a coordinated response from the United Nations system and partners.

Urgent funds are required to support the implementation of national response plans and address the broader social and economic challenges that lie ahead. The United Nations Zika Response Multi-Partner Trust Fund will directly support the Zika Strategic Response Framework, developed by the World Health Organization (WHO) in consultation with United Nations agencies, partners, and international epidemiological experts.

Donors contribute to a central point and an Advisory Committee directs funds to the highest-priority activities in the affected countries…

.
Finding Zika one paper disc at a time
May 06, 2016, 12:00 ET
An international, multi-institutional team of researchers led by synthetic biologist James Collins, Ph.D., at the Wyss Institute for Biologically Inspired Engineering at Harvard University, has developed a low-cost, rapid paper-based diagnostic system for strain-specific detection of the Zika…

EBOLA/EVD [to 7 May 2016]

EBOLA/EVD [to 7 May 2016]
“Threat to international peace and security” (UN Security Council)

Editor’s Note:
While WHO issued an integrated situation report on 28 April 2016 covering Zika,Yellow Fever and Ebola, we did not identify an update to this report on the WHO website, although separate Zika and Yellow Fever situation reports were posted as captured in this week’s edition. Given that a fresh risk assessment on Ebola was included, we presume the risk assessment remains current as below.
.
Situation Report – Zika Virus Disease, Yellow Fever, Ebola Virus Disease – 28 April 2016
[Excerpt]
Ebola Virus Disease
Risk assessment:
Although all of the previous outbreaks have been stopped, the performance indicators suggest that the three countries still have variable capacity to prevent (care for survivors), detect (epidemiological and laboratory surveillance) and respond to new outbreaks (Table 7). The risk of additional outbreaks remains.

.
Beyond Ebola, keeping patients and health workers safe
5 May 2016

.
Liberia and Guinea discharge final Ebola patients in latest flare-up and begin 42 days of heightened surveillance
2 May 2016
Liberia’s Ministry of Health, WHO and partners held a ceremony at the Ebola treatment facility in Monrovia to celebrate the recovery and discharge of a 2-year-old boy, the final patient in a latest flare-up in Liberia. His 5-year-old brother recovered a week earlier.

POLIO [to 7 May 2016]

POLIO [to 7 May 2016]
Public Health Emergency of International Concern (PHEIC)

.

Polio this week as of 4 May 2016
:: From the 17 April to the 1 May, 155 countries and territories participated in the historic trivalent to bivalent oral polio vaccine switch, withdrawing the type two component of the vaccine to protect future generations against circulating vaccine derived polioviruses. Track the switch live.

:: A group of independent experts in Ukraine met to assess the country’s response to the polio outbreak and concluded that transmission of the poliovirus has likely stopped in the country. However, they emphasized the need to continue to strengthen immunization and surveillance to protect children in Ukraine against further outbreaks.

The Trivalent to Bivalent Oral Polio Vaccine Switch
:: Between 17 April and 1 May, the type 2 component of the oral polio vaccine (OPV) is being removed from use through a globally synchronized switch from the trivalent to bivalent oral polio vaccine. This is the first stage of objective 2 of the Polio Eradication and Endgame Strategic Plan 2013-2018 to withdraw OPV in a phased manner starting with the type 2 component following the eradication of wild poliovirus type 2 in September 2015.

:: Thanks to the efforts of a wide range of stakeholders from Ministries of Health, health workers, volunteers, switch monitors, WHO, UNCEF and partners of the World Health Organization, confirmation has been received that 152 countries have completed the switch.

:: Follow a live update of which countries have undergone the switch here. Learn more about why the switch is such an important part of ensuring a polio-free world through this series of videos.

The following indicators are being carefully tracked to ensure the switch goes smoothly. As of 3 May:
:: 152 of 155 (98%) countries and territories have stopped using the trivalent oral polio vaccine.
:: Independent monitoring to ensure the switch goes smoothly has begun in 126 of 153 countries (82%).
:: The National Validation Committee has received switch monitoring data from 16 of 153 countries.
:: The WHO Regional Office has received the National Validation Report from 10 countries.

Selected Country Levels Updates [excerpted]
Pakistan
:: One new case of wild poliovirus type 1 (WPV1) was reported in the last week in Shikarpur district of Sindh province, with onset of paralysis on 12 April. The total number of WPV1 cases for 2016 is now nine, compared to 22 reported at the same date last year.

.

EU supports UNICEF and WHO with €3 million in humanitarian aid for polio vaccinations in Syria
Date: 03/05/2016
Today the European Commission has announced €3 million in humanitarian funding for a UNICEF and World Health Organisation-led nationwide polio vaccination campaign in Syria.
The campaign aims to reach 2 million children in areas where medical access remains critical, such as in besieged, hard-to-reach and under-served areas…

Today’s funding is part of the €445 million in humanitarian aid, announced at the London donors’ conference, that the Commission will provide in 2016 for the crisis in Syria.

The EU is a leading donor in the international response to the Syrian crisis. Over €5 billion in humanitarian, development, economic and stabilisation assistance has been provided so far by the EU and Member States collectively…

.

UNOG – Information Service [to 7 May 2016]
6 May 2016
Syria – REGULAR PRESS BRIEFING BY THE INFORMATION SERVICE
In response to a question, Mr. Jasarevic said that there had been a sub-national polio immunization campaign in different parts of Syria. In Aleppo, there had been a campaign from 24 to 28 April.

.

WHO: Poliomyelitis (polio) transmission in Ukraine interrupted, but efforts must continue to protect children
06-05-2016
A team of technical experts assessed Ukraine’s response to a polio outbreak and concluded that transmission of poliovirus has been interrupted. Nevertheless, the team remains concerned about significant gaps in immunization and surveillance that put Ukraine at high risk for new outbreaks.

“Thanks to the efforts of the Ministry of Health, health workers and parents, many more children are vaccinated against polio, and I commend them for their commitment,” said Dr Zsuzsanna Jakab, WHO Regional Director for Europe. “But these efforts do not stop now. The immunization gap persists and, if Ukraine does not continue vaccinating its children, this gap will expand for polio and other vaccine-preventable diseases to strike.”

High routine immunization coverage
Owing to low coverage, immunization gaps accumulated in Ukraine; it interrupted polio transmission with a campaign of three rounds of catch-up vaccination. High routine immunization coverage is a top priority for WHO, to ensure that another outbreak of polio or any other vaccine-preventable disease does not hit the country.

“We need to seize the momentum gained during the polio outbreak to strengthen Ukraine’s immunization programme, so that parents may exercise their right and responsibility to vaccinate their children,” said Dr Luigi Migliorini, WHO Representative in Ukraine.
With the United Nations Children’s Fund (UNICEF), WHO is supporting the Ministry of Health in making vaccines available to close the country’s immunization gap and protect against all vaccine-preventable diseases.

Recommendations of the expert team
“An expert team from different United Nations agencies and partners assessed the polio-outbreak response over two weeks in five Ukrainian regions, at both oblast and rayon levels. Experts analysed the disease surveillance systems, supplementary immunization activities, and communications “, said Dr Patrick O’Connor, leader of the WHO assessment team.

As well as concluding that poliovirus transmission in Ukraine had been interrupted, the team recommended key actions to mitigate the risk of future outbreaks:
:: increase political commitment for childhood immunization;
:: re-establish high, uniform immunization coverage with polio vaccines;
:: improve the communication skills of frontline health workers; and
:: enhance surveillance for early detection of polioviruses…

Yellow Fever [to 7 May 2016]

Yellow Fever [to 7 May 2016]
http://www.who.int/emergencies/yellow-fever/en/

.
Editor’s Note:
Yellow Fever information is now aggregated on a separate page with its own situation report as below.
.

Yellow Fever – Situation Report – 5 May 2016
SUMMARY
:: A yellow fever outbreak was detected in Angola late in December 2015 and confirmed by the Institut Pasteur Dakar (IP-D) on 20 January 2016. Subsequently, a rapid increase in the number of cases has been observed.
:: As of 4 May 2016, Angola has reported 2149 suspected cases of yellow fever with 277 deaths. Among those cases, 661 have been laboratory confirmed. Despite vaccination campaigns in Luanda, there is still circulation of the virus in most districts of Luanda and in five additional provinces.
:: Three countries have reported confirmed yellow fever cases exported from Angola: Democratic Republic of The Congo (DRC) (37 cases), Kenya (two cases) and People’s Republic of China (11 cases). Namibia has also reported a suspect yellow fever case exported from Angola. This highlights the risk of international spread through non-immunised travellers.
:: On 22 March 2016, the Ministry of Health of DRC notified human cases of yellow fever in connection with Angola. The Government officially declared the yellow fever outbreak on 23 April. As of 4 May, DRC has reported 5 probable cases and 39 laboratory confirmed cases: 37 imported from Angola, reported in Kongo central province and Kinshasa and two autochthonous cases in Ndjili, Kinshasa and Matadi, Kongo central province. The possibility of locally acquired infections is under investigation for at least 10 non-classified cases in both Kinshasa and Kongo central provinces.
:: In Uganda, the Ministry of Health notified yellow fever cases in Masaka district on 9 April 2016. As of 4 May, seven yellow fever cases are laboratory confirmed in three districts: Masaka, Rukungiri and Kalangala. According to sequencing results, those clusters are not epidemiologically linked to Angola.
:: The virus in Angola and DRC is largely concentrated in main cities and is likely to have been introduced to the cities following increased yellow fever viral circulation among monkeys in the forest.

Risk assessment
:: Persistent local transmission in Luanda despite the fact that almost six million people have been vaccinated.
:: Local transmission reported in six highly populated provinces including Luanda.
:: High risk of spread to neighbouring countries. Confirmed cases have already travelled from Angola to People’s Republic of China , DRC and Kenya. As the borders are porous with substantial crossborder social and economic activities, further transmission cannot be excluded. Viraemic patients travelling pose a risk for the establishment of local transmission especially in countries where adequate vectors and susceptible human populations are present.
:: For DRC, a field investigation conducted in April concluded that there is a high risk of local transmission of yellow fever in the country. Given the limited availability of vaccines, the large Angolan community in Kinshasa, the porous border between Angola and DRC and the presence and the activity of the vector Aedes in the country, the situation needs to be monitored with extreme attention.

.
Disease Outbreak News (DONs)
:: Yellow fever – Uganda 2 May 2016
:: Yellow fever – Democratic Republic of the Congo 2 May 2016

.
Yellow fever – REGULAR PRESS BRIEFING BY THE INFORMATION SERVICE
UNOG [Geneva] Information Service 6 May 2016
…Mr. Jasarevic said that the outbreak of yellow fever which had started in December 2015 in Angola was of particular concern to WHO, as for the first time in a very long time there had been transmission of the virus in the capital, Luanda, and in other major urban centers. Local transmission, not related to travel from Angola, had also been confirmed in two cases in the Democratic Republic of the Congo. Exported cases from Angola had been recorded in China and Kenya. A large-scale vaccination campaign was continuing in Angola. The International Coordinating Mechanism (composed of the WHO, UNICEF; MSF and ICRC) had dispatched more than 11 million vaccines to Angola, with the last 2.4 million expected to arrive today and on 10 May. More than 7 million people had been vaccinated in Luanda and in the Huambo and Benguela provinces. The WHO is aiming to have more than 80 per cent of people vaccinated order to contain transmission. Some 2.2 million doses of the vaccine were on their way to the Democratic Republic of the Congo and were scheduled to arrive on 11 May. Uganda was also experiencing a yellow fever outbreak, but this outbreak was not believed to be linked to the one in Angola.

WHO had set up incident management teams in Angola, Democratic Republic of the Congo, and also in Geneva, working with the WHO regional office to accelerate efforts to combat the outbreak. WHO was also supporting Ministires of Health in Angola and DRC to coordinate the health response in the areas of immunization, to ensure rapid detection and laboratory confirmation of suspect cases, to implement integrated vector control activities and to establish and reinforce community-led social mobilization activities. Moreover, WHO was working with neighboring countries such as Namibia and Zambia to strengthen cross-border surveillance to reduce the spread of infection. A travel advisory had been issued to inform travellers that yellow fever vaccination was required. People leaving the country at exit points to neighboring countries were now being asked to produce proof of vaccination against yellow fever.

As of 4 May, 2,148 suspected cases of yellow fever had bene reported in Angola, with 277 deaths. Among those cases, 641 had been laboratory-confirmed. In the DRC, the Government had officially declared a yellow fever outbreak on 23 April, and as of 4 May the country had reported 5 probable cases and 39 laboratory-confirmed cases. Out of the 39, 37 had been imported from Angola and 2 were due to local transmission. In China, there had been 11 confirmed cases which had been travel-related, and in Kenya, 2 confirmed cases.

In response to questions, Mr. Jasarevic said that the outbreak had started in late December 2015. The majority of the cases in the DRC had been linked to the Angola outbreak through travel, but now, there were two confirmed cases of local transmission by the Aedes mosquito. There was no shortage, but rather a limited supply of vaccines. In the world, there were four manufacturers with an annual production of up to 80 million doses. There were 48 countries in Africa and in Latin America which were considered endemic and used routine immunization (this had been the case of Angola since 1997), which accounted for about 30 million doses. However, a significant proportion of the population was not being vaccinated, and mass vaccination was used whenever there was an outbreak, accounting for another 30 to 35 million doses. Finally, a stockpile of vaccines was managed by the international group composed of the WHO, UNICEF; MSF and ICRC, releasing vaccines whenever there were outbreaks. WHO was working with the manufacturer to see how production could be increased. Two out of the four manufacturers would be able to increase production in the coming years. Demand had been fuelled by the introduction of the yellow fever initiative.

Mr. Jasarevic also clarified that there was no evidence to support a link between the Angola and Uganda outbreaks. Local transmission versus travel-related transmission was determined by looking at epidemiological history and at the virus itself in the lab, but further details on this would be provided by the WHO during the 10 May press conference. From an epidemiological point of view it was important to know where the outbreak had started.

WHO & Regional Offices [to 7 May 2016]

WHO & Regional Offices [to 7 May 2016]

Weekly Epidemiological Record (WER) 6 May 2016, vol. 91, 18 (pp. 237–248)
Contents
237 Policy statement on data sharing by WHO in the context of public health emergencies (as of 13 April 2016)
[see full text above]
240 Global measles and rubella laboratory network support for elimination goals, 2010–2015
247 Monthly report on dracunculiasis cases, January– March 2016

.
GIN – April 2016 pdf, 1.97Mb

.
Disease Outbreak News (DONs)
:: Human infection with avian influenza A(H7N9) virus – China 3 May 2016
:: Yellow fever – Uganda 2 May 2016
:: Yellow fever – Democratic Republic of the Congo 2 May 2016

.
:: WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: Dr Matshidiso Moeti, WHO Regional Director for Africa, calls for change in approach to health systems strengthening to achieve the SDGs
Johannesburg, 06 May 2016 – The World Health Organization Regional Director for Africa, Dr. Matshidiso Moeti has called for a change in approach from treating single diseases to promoting health, and to investing in strong national health systems in order to be able to deliver on people’s demands and expectations.
:: Closing doors stops deadly surgical site infections in Uganda – 04 May 2016
:: WHO launches a manual proposing effective and sustainable oral health solutions for Africa – 04 May 2016

WHO Region of the Americas PAHO
No new content identified.

WHO South-East Asia Region SEARO
No new content identified.

WHO European Region EURO
:: Poliomyelitis (polio) transmission in Ukraine interrupted, but efforts must continue to protect children 06-05-2016
:: Country-by-country profiles on national health situation relaunched 06-05-2016

WHO Eastern Mediterranean Region EMRO
:: Fifth seminar on health diplomacy convenes in Cairo
Cairo, 7 May 2016 – The WHO Regional Office for the Eastern Mediterranean is holding its fifth annual seminar on health diplomacy from 7 to 8 May 2016 in Cairo, Egypt. The seminar was first convened in 2012 as a regional initiative bringing together representatives of ministries of health and foreign affairs to explore the multidimensional relationships between health and foreign policy. It has since evolved into an annual event, which, this year, hosts more than 70 ministers of health, senior officials from ministries of foreign affairs and ministries of health, ambassadors, representatives of United Nations missions in Geneva, deans of diplomatic institutes, parliamentarians and global health diplomacy experts from around the world.

WHO Western Pacific Region
:: The Western Pacific Region takes part in a global switch to a new polio vaccine: A key step in achieving a polio free world
MANILA, 5 May 2016 – In the largest synchronized event in the history of vaccines, 155 countries and areas have simultaneously participated in the switch to a new oral polio vaccine (OPV) between 17 April and 1 May. 16 Member States in the Western Pacific Region successfully made the switch…

CDC/ACIP [to 7 May 2016]

CDC/ACIP [to 7 May 2016]
http://www.cdc.gov/media/index.html
[see Zika coverage above which includes CDC briefing content]

THURSDAY, MAY 5, 2016
CDC adds Peru to interim travel guidance related to Zika virus
Today, CDC posted a Zika virus travel notice for Peru. CDC has issued travel notices (level 2, “practice enhanced precautions”) for people traveling to destinations with Zika.

WEDNESDAY, MAY 4, 2016
Hepatitis C Kills More Americans than Any Other Infectious Disease – Press Release

.

MMWR May 6, 2016 / Vol. 65 / No. 17
:: Global Measles and Rubella Laboratory Network Support for Elimination Goals, 2010–2015
:: Update: Ongoing Zika Virus Transmission — Puerto Rico, November 1, 2015–April 14, 2016
:: Notes from the Field: Assessment of Health Facilities for Control of Canine Rabies — Gondar City, Amhara Region, Ethiopia, 2015
:: Announcement: Updated Guidelines for Antiretroviral Postexposure Prophylaxis after Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV — United States, 2016

MSF/Médecins Sans Frontières [to 7 May 2016]

MSF/Médecins Sans Frontières [to 7 May 2016]
http://www.doctorswithoutborders.org/news-stories/press/press-releases

.
Field news
Responding to a Meningitis Outbreak in Niger
May 05, 2016
Since the beginning of 2016, an outbreak of meningitis C has hit every region of Niger. Doctors Without Borders/Médecins Sans Frontières (MSF) emergency teams have been working with the Nigerien Ministry of Health (MoH) to contain the epidemic since January. The number of weekly cases is now decreasing, but there are insufficient stocks of vaccine available to protect those at risk in the event of another outbreak.

According to official figures, 1,199 cases of meningitis C have been identified and 87 people have died of the disease, mostly in the western part of the country. There was a steady rise in cases from January to mid-March, after which the number of new infections started to fall.
Since the beginning of the epidemic, MSF has been supporting the MoH in monitoring the affected areas, vaccinating people, and providing free treatment to patients. To contain the epidemic in the worst-affected areas, MSF conducted targeted vaccination campaigns in collaboration with the MoH. More than 254,000 people were vaccinated in the health districts of Tillabéri, Dosso, and Tahoua regions, using doses obtained from the International Coordination Group for the supply of vaccines, as well as MoH and MSF stocks. Another 126,000 vaccine doses are expected to arrive at the end of April.

A Lack of Vaccines Worldwide
According to the preparedness and response plan for meningitis epidemics in Niger, 2.8 million people should be vaccinated if an outbreak affects 21 health districts. Thus far, however, immunization campaigns have been carried out in just six. “The problem is that, nationally and globally, not enough meningitis C vaccines are available and the vaccine is expensive,” says Dr. Idrissa Compaoré, MSF medical coordinator. “Manufacturers need to urgently increase their production and sell it at an affordable price, but they are not doing so.”

In addition to organizing vaccination activities, MSF works with the MoH to prevent new cases by training public sector laboratory staff in diagnostics, testing, and the transport of samples. “If we don’t have vaccines, it is essential that we identify and confirm new cases as soon as possible, to prevent the disease from spreading. Information must be collected and shared, and patients treated without delay,” says Dr. Compaoré…

IVI – International Vaccine Institute [to 7 May 2016]

IVI – International Vaccine Institute [to 7 May 2016]
http://www.ivi.org/web/www/home

.
[undated]
IVI Appoints Jee, Youngmee, Hanna Nohynek, and Lee, Kyu Hyung to its Board of Trustees
The International Vaccine Institute (IVI) today announced the appointments of Dr. Jee, Youngmee, Mr. Lee, Kyu Hyung, and Dr. Hanna Nohynek to its Board of Trustees. Dr. Jee’s appointment was effective as of April 5, 2016 while Mr. Lee and Dr. Nohynek will start their term on May 24, 2016.

“Dr. Jee and Dr. Nohynek are well-respected physicians and scientists from South Korea and Finland, while Mr. Lee is a distinguished veteran diplomat from South Korea,” said Dr. Jerome Kim, IVI Director General. “They bring leadership experience from their respective fields of virology, vaccinology, and foreign affairs, and I am pleased that they are joining IVI’s board.”
Dr. Jee, Youngmee is Director General of the Center for Pathology and Immunology at the National Institute of Health, Korea Centers for Disease Control & Prevention (KCDC)…

Mr. Lee, Kyu Hyung is Advisor to the Samsung Economic Research Institute. A career diplomat for more than 35 years, Mr. Lee was the South Korean Ambassador to China, Bangladesh, and Russia…

Dr. Hanna Nohynek is Chief Medical Officer, Team Leader of Vaccine Programme Development at National Institute for Health and Welfare (THL) in Finland…

.

[undated]
New Appointments on IVI Management Team
– New Deputy Director General of Government Affairs & Governance, Head of Biostatistics, and Head of Program Management onboard
These new appointments reflect the strategic and organizational changes taking place at IVI since January, 2016. Key hires and appointments have been made over the past few months as part of IVI’s strategic renewal. These individuals bring seniority and experience in vaccine-related research and management to IVI, and they are instrumental in bolstering IVI’s scientific leadership, management and operations.

Dr. Han, Kyung-Taik is the Deputy Director General of IVI’s Government Affairs & Governance Unit as of April 4, 2016. This newly established unit will oversee engagement with the Korean government and other stakeholders in the Republic of Korea (IVI’s host country), and ensure that governance and internal control are in compliance with donor requirements and international accounting standards. As Deputy Director General, Dr. Han will also serve on IVI’s leadership team…

Dr. Julia A. Lynch is the Head of IVI’s Program Management Unit, effective May 6, 2016. This unit will be responsible for project management and grant management…

Dr. Yun Chon is the Head of IVI’s Biostatistics & Data Management Department as of April 1, 2016. This department, under the Development & Delivery Unit, is responsible for biostatistics and data management in support of IVI’s research activities including epidemiologic and clinical studies. The department also provides training and technical support to IVI collaborators and their research activities from middle- and low-income countries….

Fondation Merieux [to 7 May 2016]

Fondation Merieux [to 7 May 2016]
Mission: Contribute to global health by strengthening local capacities of developing countries to reduce the impact of infectious diseases on vulnerable populations.
http://www.fondation-merieux.org/news

.
5 May 2016, Port-au-Prince (Haiti)
SPHaïtiLAB Conducts 1st Assessment of Biomedical Analysis Laboratories in Haiti
Providing essential data to build a national laboratory policy tailored to the country’s needs.
The 1st assessment of biomedical analysis laboratories in Haiti is presented today at the Kinam Hotel, under the high authority of the Ministry of Public Health and Population. Mr. Vincent Degert, European Union Ambassador to Haiti, Mrs. Elisabeth Beton Delègue, French Ambassador to Haiti, Dr. Jacques Boncy, Director of the National Public Health Laboratory (LNSP), Dr. Paul Adrien, Director of the Department of Laboratory and Research Epidemiology (DELR), Dr. Stalz Charles Vilbrun of the Haitian Group for the Study of Kaposi’s Sarcoma and Opportunistic Infections (GHESKIO) and Mr. Benoît Miribel, Director General of Fondation Mérieux, as well as representatives from WHO, the U.S. CDC and Agence Française de Développement (AFD) will also be among the participants. This analysis is the first result of the SPHaïtiLAB project, designed by the LNSP as part of the Ministry of Public Health and Population’s ambitious plan to reinforce the country’s laboratory sector.

On the occasion of this presentation, the European Union Ambassador to Haiti, Vincent Degert, declared: “The European Union is proud to support this initiative for which it has mobilized a 1,432,000 euro funding package. This project is very timely to help improve epidemiological surveillance, an essential part of a health system.” He went on to add: “Health, like education, is the measure of a country’s human development. We hope that this project, by supporting the country’s main stakeholders in health and laboratory policy, will effect real change in the prevention of disease and help fulfill the legitimate aspiration of each and every Haitian to benefit fully from the well-being and harmony that good health brings.”

The laboratory plays a vital role, giving doctors the information they need to provide good patient care. It is also an essential tool for the surveillance of epidemics. SPHaïtiLAB aims to improve the health of the Haitian population by providing analysis and strategic advice on laboratory and research policy. Funded by the European Union, the project is led by the LNSP in partnership with the DELR, the GHESKIO Centers and the African Institute of Public Health (IASP) of Burkina Faso. Fondation Mérieux manages the project and provides financial support…

Global Fund [to 7 May 2016]

Global Fund [to 7 May 2016]
http://www.theglobalfund.org/

.
03 May 2016
Luxembourg Increases Contribution to the Global Fund
LUXEMBOURG – Luxembourg is increasing its financial commitment to the Global Fund for the next three-year replenishment cycle starting in 2017, to €8.1 million, an 8 percent increase from the last replenishment period.

Romain Schneider, Minister for Development Cooperation and Humanitarian Affairs, announced the increase today at a meeting in Luxembourg with Mark Dybul, Executive Director of the Global Fund.

AERAS [to 7 May 2016]

AERAS [to 7 May 2016]
http://www.aeras.org/pressreleases

.
May 4 , 2016
Healthcare Workers Face Up To Six Times the Risk of Drug-Resistant Tuberculosis as General Population
Editor’s note: these studies are being released in the May 15 print edition of a special supplement to the journal Clinical Infectious Diseases titled “Healthcare Workers and Tuberculosis Prevention”. The full supplement is free to view.

New research suggests urgent action needed to combat tuberculosis among healthcare workers in poorer countries
.
ROCKVILLE, Md., USA Globally, healthcare workers face three times the risk of contracting tuberculosis as the general population, and the risks of multidrug-resistant disease is higher still: up to six times higher for healthcare workers in South Africa, according to new reports that are part of a healthcare worker-focused supplement in the journal Clinical Infectious Diseases. Up to one-third of affected healthcare workers die of this airborne disease.

Study authors reported that risks are compounded by the lack of an effective vaccine and facilitated by neglect of basic infection control measures such as adequate ventilation. Furthermore, young, vulnerable healthcare workers often fail to appreciate the risks they face. Therefore, health workers who are crucial to ending the epidemic frequently become both victims and transmitters of the disease.

“A person dies every 21 seconds from tuberculosis, some of whom are frontline caregivers,” said Thomas G. Evans, co-editor of the special supplement of articles and formerly Chief Scientific Officer at Aeras, a nonprofit, global biotech organization developing new tuberculosis vaccines. “Ending the epidemic requires resources, political will, and innovation, starting with protection of our health workforce.” …

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Vaccines and Global Health: The Week in Review has expanded its coverage of new reports, books, research and analysis published independent of the journal channel covered in Journal Watch below. Our interests span immunization and vaccines, as well as global public health, health governance, and associated themes. If you would like to suggest content to be included in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

On the fast track to ending the AIDS epidemic

On the fast track to ending the AIDS epidemic
Implementation of the Declaration of Commitment on HIV/AIDS and the Political Declarations on HIV and AIDS
Report of the Secretary-General
A/70/811 :: 31 pages
UN General Assembly; Seventieth session ; Agenda item 11
[Excerpts: report paragraphs which reference vaccines]
.
7. Ending AIDS requires HIV and other health and social needs to be met throughout a lifetime, including when a person is at risk of acquiring HIV, when a person requires lifetime access to treatment and when an individual, family or community may have to care for orphans and people living with HIV. Ending AIDS demands focusing resources in the countries, districts, subdistricts and city boroughs most affected and tailoring services to populations at risk and communities living in fragile contexts. It requires people-centred innovation, from transforming and reinforcing community-and facility-based service delivery to developing more effective, affordable health products, including a vaccine and cure.

39. Ending the AIDS epidemic is only possible if all people living with and affected by HIV can access affordable, quality health products. Innovation is required to enable access to point-of-care diagnostics and affordable, optimized prevention tools, including women-initiated technologies, and medicines including second-and third-line antiretroviral therapy regimens and for tuberculosis and hepatitis B and C, as well as a vaccine and cure. Recognizing that countries of all income levels struggle to provide access to affordable, quality medicines, vaccines and diagnostics, I have convened a high-level panel on access to medicines. The panel is mandated to assess and recommend solutions for remedying the policy incoherence among the rights of inventors, international human rights law, trade rules and public health, and will deliver its final report in June 2016.

64. Delivery of innovative products must be further encouraged through scaled-up investments in research and the development of more tolerable, efficacious and affordable health products, including: simpler, longer-lasting drug formulations for children, adolescents and adults; second-and third-line therapy; diagnostics; prevention technologies, including vaccines; and a cure.

V. Embracing sustainable development solutions to fast-track an accelerated, rights-based AIDS response: Recommendations
…(j) Boldly pursue new scientific solutions and expand investment in research and development for improved diagnostics, easier and more tolerable treatment regimens, therapeutic vaccines and other prevention technologies as well as a functional cure and ensure affordability by aligning trade rules and public health objectives under a human rights framework…

.
Press release
New report shows that urgent action is needed to end the AIDS epidemic by 2030
NEW YORK, 06 May 2016—A new report released by the United Nations Secretary-General, Ban Ki-moon, warns that the AIDS epidemic could be prolonged indefinitely if urgent action is not implemented within the next five years. The report, On the Fast-Track to end the AIDS epidemic, reveals that the extraordinary acceleration of progress made over the past 15 years could be lost and urges all partners to concentrate their efforts to increase and front-load investments to ensure that the global AIDS epidemic is ended as a public health threat by 2030…

:: Journal Watch

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

  If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

American Journal of Tropical Medicine and Hygiene – May 2016

American Journal of Tropical Medicine and Hygiene
May 2016; 94 (5)
http://www.ajtmh.org/content/current

.
Perspective Piece
Modeling Key Malaria Drugs’ Impact on Global Health: A Reason to Invest in the Global Health Impact Index
Nicole Hassoun
Am J Trop Med Hyg 2016 94:942-946; Published online February 8, 2016, doi:10.4269/ajtmh.15-0409
Abstract
Millions of people cannot access good quality essential medicines they need for some of the world’s worst diseases like malaria. The World Health Organization estimates that, in 2013, 198 million people became sick with malaria and 584,000 people died of the disease, while the Institute for Health Metrics Evaluation estimates that there were 164,929,872 cases of malaria in 2013 and 854,568 deaths in 2013. There are many attempts to model different aspects of the global burden of tropical diseases like malaria, but it is also important to measure success in averting malaria-related death and disability. This perspective proposes investing in a systematic effort to measure the benefits of health interventions for malaria along the lines of a model embodied in the Global Health Impact Index (global-health-impact.org).

.
Surveying the Knowledge and Practices of Health Professionals in China, India, Iran, and Mexico on Treating Tuberculosis
Steven J. Hoffman, G. Emmanuel Guindon, John N. Lavis, Harkanwal Randhawa, Francisco Becerra-Posada, Masoumeh Dejman, Katayoun Falahat, Hossein Malek-Afzali, Parasurama Ramachandran, Guang Shi, and C. A. K. Yesudian
Abstract
Research evidence continues to reveal findings important for health professionals’ clinical practices, yet it is not consistently disseminated to those who can use it. The resulting deficits in knowledge and service provision may be especially pronounced in low- and middle-income countries that have greater resource constraints. Tuberculosis treatment is an important area for assessing professionals’ knowledge and practices because of the effectiveness of existing treatments and recognized gaps in professionals’ knowledge about treatment. This study surveyed 384 health professionals in China, India, Iran, and Mexico on their knowledge and practices related to tuberculosis treatment. Few respondents correctly answered all five knowledge questions (12%) or self-reported performing all five recommended clinical practices “often or very often” (3%). Factors associated with higher knowledge scores included clinical specialization and working with researchers. Factors associated with better practices included training in the care of tuberculosis patients, being based in a hospital, trusting systematic reviews of randomized controlled double-blind trials, and reading summaries of articles, reports, and reviews. This study highlights several strategies that may prove effective in improving health professionals’ knowledge and practices related to tuberculosis treatment. Facilitating interactions with researchers and training in acquiring systematic reviews may be especially helpful.

.
Effectiveness of Oral Cholera Vaccine in Haiti: 37-Month Follow-Up
Karine Sévère, Vanessa Rouzier, Stravinsky Benedict Anglade, Claudin Bertil, Patrice Joseph,
Alexandra Deroncelay, Marie Marcelle Mabou, Peter F. Wright, Florence Duperval Guillaume,
and Jean William Pape
Am J Trop Med Hyg 2016 94:1136-1142; Published online February 29, 2016, doi:10.4269/ajtmh.15-0700
Abstract
The first oral cholera vaccine (OCV) campaign, since its prequalification by the World Health Organization, in response to an ongoing cholera epidemic (reactive vaccination) was successfully conducted in a poor urban slum of approximately 70,000 inhabitants in Port-au-Prince, Haiti, in 2012. Vaccine coverage was 75% of the target population. This report documents the impact of OCV in reducing the number of culture-confirmed cases of cholera admitted to the Groupe Haïtien d’Etude du Sarcome de Kaposi et des Infections Opportunistes (GHESKIO) cholera treatment center from that community in the 37 months postvaccination (April 2012–April 30, 2015). Of 1,788 patients with culture-confirmed cholera, 1,770 (99%) were either from outside the vaccine area (1,400 cases) or from the vaccinated community who had not received OCV (370 cases). Of the 388 people from the catchment area who developed culture-confirmed cholera, 370 occurred among the 17,643 people who had not been vaccinated (2.1%) and the remaining 18 occurred among the 52,357 people (0.034%) who had been vaccinated (P < 0.001), for an efficacy that approximates 97.5%. Despite not being designed as a randomized control trial, the very high efficacy is a strong evidence for the effectiveness of OCV as part of an integrated package for the control of cholera in outbreak settings.

.
Use of Balanced Scorecard Methodology for Performance Measurement of the Health Extension Program in Ethiopia
Hailay D. Teklehaimanot, Awash Teklehaimanot, Aregawi A. Tedella, and Mustofa Abdella
Am J Trop Med Hyg 2016 94:1157-1169; Published online February 29, 2016, doi:10.4269/ajtmh.15-0192
Abstract
In 2004, Ethiopia introduced a community-based Health Extension Program to deliver basic and essential health services. We developed a comprehensive performance scoring methodology to assess the performance of the program. A balanced scorecard with six domains and 32 indicators was developed. Data collected from 1,014 service providers, 433 health facilities, and 10,068 community members sampled from 298 villages were used to generate weighted national, regional, and agroecological zone scores for each indicator. The national median indicator scores ranged from 37% to 98% with poor performance in commodity availability, workforce motivation, referral linkage, infection prevention, and quality of care. Indicator scores showed significant difference by region (P < 0.001). Regional performance varied across indicators suggesting that each region had specific areas of strength and deficiency, with Tigray and the Southern Nations, Nationalities and Peoples Region being the best performers while the mainly pastoral regions of Gambela, Afar, and Benishangul-Gumuz were the worst. The findings of this study suggest the need for strategies aimed at improving specific elements of the program and its performance in specific regions to achieve quality and equitable health services.

Annals of Internal Medicine – 3 May 2016

Annals of Internal Medicine
3 May 2016, Vol. 164. No. 9
http://annals.org/issue.aspx

.
Original Research
Safety of Seasonal Influenza Vaccination in Hospitalized Surgical Patients: A Cohort Study
Sara Y. Tartof, PhD; Lei Qian, PhD; Gunter K. Rieg, MD; Kalvin C. Yu, MD; Lina S. Sy, MPH; Hung Fu Tseng, PhD; Rulin C. Hechter, MD, PhD; and Steven J. Jacobsen, MD, PhD
Abstract
Background: Despite recommendations to vaccinate surgical inpatients against influenza, vaccination rates remain low in this population, due in part to concerns about potential negative effects on postsurgical care.
Objective: To evaluate whether influenza vaccination in the perioperative period increases health care utilization and evaluations for postsurgical infection after discharge.
Design: Retrospective cohort study.
Setting: Members of Kaiser Permanente Southern California.
Participants: Patients aged 6 months or older who had inpatient surgery with admission and discharge between 1 September and 31 March from 2010 to 2013.
Measurements: All influenza vaccinations administered between 1 August and 30 April in the 2010–2011, 2011–2012, and 2012–2013 influenza seasons. Outcomes included rates of outpatient visits, readmission, emergency department (ED) visits, fever (temperature ≥38.0 °C), and clinical laboratory evaluations for infection (urine culture, complete blood count, blood culture, and wound culture) in the 7 days after discharge.
Results: Of the 42 777 surgeries included in adjusted analyses, vaccine was administered during hospitalization in 6420. No differences were detected between the vaccinated and unvaccinated groups in risk for inpatient visits (rate ratio [RR], 1.12 [95% CI, 0.96 to 1.32]), ED visits (RR, 1.07 [CI, 0.96 to 1.20]), postdischarge fever (RR, 1.00 [CI, 0.76 to 1.31]), or clinical evaluations for infection (RR, 1.06 [CI, 0.99 to 1.13]). A marginal increase in risk for outpatient visits (RR, 1.05 [CI, 1.00 to 1.10]; P = 0.032) was found.
Limitation: The study did not distinguish between planned and unplanned readmissions or outpatient visits.
Conclusion: No strong evidence of increased risk for adverse outcomes was found in comparisons of patients who received influenza vaccine during a surgical hospitalization and those who did not. The data support the recommendation to vaccinate surgical inpatients against influenza.

.

Ideas and Opinions
Zika Virus: Rapid Spread in the Western Hemisphere FREE
Lin H. Chen, MD; and Davidson H. Hamer, MD

BMC Infectious Diseases (Accessed 7 May 2016)

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 7 May 2016)

.
Research article
The effect of early versus late treatment initiation after diagnosis on the outcomes of patients treated for multidrug-resistant tuberculosis: a systematic review
Globally it is estimated that 480 000 people developed multidrug-resistant tuberculosis (MDR-TB) in 2014 and 190 000 people died from the disease. Successful treatment outcomes are achieved in only 50 % of patients…
Rebecca C. Harris, Louis Grandjean, Laura J. Martin, Alexander J. P. Miller, Joseph-Egre N. Nkang, Victoria Allen, Mishal S. Khan, Katherine Fielding and David A. J. Moore
BMC Infectious Diseases 2016 16:193
Published on: 4 May 2016

.

Research article
Factors effecting influenza vaccination uptake among health care workers: a multi-center cross-sectional study
The present study aimed to identify factors affecting vaccination against influenza among health professionals.
Süheyl Asma, Hülya Akan, Yücel Uysal, A. Gürhan Poçan, Mustafa Haki Sucaklı, Erhan Yengil, Çiğdem Gereklioğlu, Aslı Korur, İbrahim Başhan, A. Ferit Erdogan, A. Kürşat Özşahin and Altuğ Kut
BMC Infectious Diseases 2016 16:192
Published on: 4 May 2016

Examining the quality of evidence to support the effectiveness of interventions: an analysis of systematic reviews

BMJ Open
2016, Volume 6, Issue 5
http://bmjopen.bmj.com/content/current

.
Evidence based practice
Research
Examining the quality of evidence to support the effectiveness of interventions: an analysis of systematic reviews
Professor Robert L Kane; kanex001@umn.edu, Mary Butler, Weiwen Ng
BMJ Open 2016;6:e011051 doi:10.1136/bmjopen-2016-011051
Abstract
Objective This analysis examines the quality of evidence (QOE) for 1472 outcomes linked to interventions where the QOE was rated in 42 systematic reviews of randomised clinical trials and/or observational studies across different topics.
Setting Not applicable.
Participants 76 systematic reviews.
Primary and secondary outcome measures Strength of evidence ratings by initial reviewers.
Results Among 76 systematic reviews, QOE ratings were available for only 42, netting 1472 comparisons. Of these, 57% included observational studies; 4% were rated as high and 12% as moderate; the rest were low or insufficient. The ratings varied by topic: 74% of the surgical study pairs were rated as low or insufficient, compared with 82% of pharmaceuticals and 86% of device studies, 88% of organisational, 91% of lifestyle studies, and 94% of psychosocial interventions.
Conclusions We are some distance from being able to claim evidence-based practice. The press for individual-level data will make this challenge even harder.

Bulletin of the World Health Organization – Volume 94, Number 5, May 2016

Bulletin of the World Health Organization
Volume 94, Number 5, May 2016, 309-404
http://www.who.int/bulletin/volumes/94/5/en/

.
Special theme: the Global strategy for women’s, children’s and adolescents’ health (2016-2030)
.
EDITORIALS
Knowledge for effective action to improve the health of women, children and adolescents in the sustainable development era
Flavia Bustreo, Robin Gorna & David Nabarro
http://dx.doi.org/10.2471/BLT.16.174243
…Achieving the global strategy and the SDGs will require the use of the best available knowledge for action, as well as investment in new research and innovation. This month’s Bulletin theme issue seeks to broaden the evidence on effective country implementation and lessons learnt from the MDGs. Kuruvilla et al.3 summarize the current global strategy, show how the objectives of the strategy are aligned with the SDGs and how selected countries are already making progress.

Several papers in this issue deal with progress on the survival objective of the global strategy; Negandhi et al.4 present a surveillance-based maternal and infant death review system in India; Murguía-Peniche et al.5 and McKinnon et al.6 address under-researched topics, such as the factors associated with stillbirths in Mexico and the high prevalence of suicidal behaviours among adolescents in low- and middle-income countries, respectively.

The strategy’s thrive objective addresses the overall health and well-being of mothers, children and adolescents. Chai et al.7 determine how exposure to violence hinders child development and can affect health across the life-course and subsequent generations. Askew et al.8 describe the importance of ensuring sexual and reproductive health and rights in humanitarian settings.

The transform objective of the strategy focuses on expanding enabling environments and aims to transform societies so that women, children and adolescents everywhere can realize their rights to the highest attainable standards of health and well-being. Several papers address the global strategy’s transform objective. Newberry et al.9 present a formal emergency response infrastructure developed in India for gender-based violence.

This special issue also includes papers on approaches that have helped countries achieve improved health outcomes for women, children and adolescents. Marston et al.10 discuss the importance of community engagement in achieving results. Ahmed et al.11 describe policies and programmes that contributed to reductions in child and maternal mortality. Frost et al.12 explain how multistakeholder dialogues are used to clarify what works and does not work in policy-making and implementation…

.
EDITORIALS
Sexual and reproductive health and rights in emergencies
Ian Askew, Rajat Khosla, Ugochi Daniels, Sandra Krause, Clare Lofthouse, Lale Say, Kate Gilmore & Sarah Zeid
http://dx.doi.org/10.2471/BLT.16.173567

.
Research
Association between intimate partner violence and poor child growth: results from 42 demographic and health surveys
Jeanne Chai, Günther Fink, Sylvia Kaaya, Goodarz Danaei, Wafaie Fawzi, Majid Ezzati, Jeffrey Lienert & Mary C Smith Fawzi
http://dx.doi.org/10.2471/BLT.15.152462
Abstract
Objective
To determine the impact of intimate partner violence against women on children’s growth and nutritional status in low- and middle-income countries.
Methods
We pooled records from 42 demographic and health surveys in 29 countries. Data on maternal lifetime exposure to physical or sexual violence by an intimate partner, socioeconomic and demographic characteristics were collected. We used logistic regression models to determine the association between intimate partner violence and child stunting and wasting.
Findings
Prior exposure to intimate partner violence was reported by 69 652 (34.1%) of the 204 159 ever-married women included in our analysis. After adjusting for a range of characteristics, stunting in children was found to be positively associated with maternal lifetime exposure to only physical (adjusted odds ratio, aOR: 1.11; 95% confidence interval, CI: 1.09–1.14) or sexual intimate partner violence (aOR: 1.09; 95% CI: 1.05–1.13) and to both forms of such violence (aOR: 1.10; 95% CI: 1.05–1.14). The associations between stunting and intimate partner violence were stronger in urban areas than in rural ones, for mothers who had low levels of education than for women with higher levels of education, and in middle-income countries than in low-income countries. We also found a small negative association between wasting and intimate partner violence (aOR: 0.94; 95%CI: 0.90–0.98).
Conclusion
Intimate partner violence against women remains common in low- and middle-income countries and is highly detrimental to women and to the growth of the affected women’s children. Policy and programme efforts are needed to reduce the prevalence and impact of such violence.

.
Perspectives
The sustainable development goals, violence and women’s and children’s health
Claudia García-Moreno & Avni Amin
http://dx.doi.org/10.2471/BLT.16.172205

.
The Global strategy for women’s, children’s and adolescents’ health (2016–2030): a roadmap based on evidence and country experience
Shyama Kuruvilla, Flavia Bustreo, Taona Kuo, CK Mishra, Katie Taylor, Helga Fogstad, Geeta Rao Gupta, Kate Gilmore, Marleen Temmerman, Joe Thomas, Kumanan Rasanathan, Ted Chaiban, Anshu Mohan, Anna Gruending, Julian Schweitzer, Hannah Sarah Dini, John Borrazzo, Hareya Fassil, Lars Gronseth, Rajat Khosla, Richard Cheeseman, Robin Gorna, Lori McDougall, Kadidiatou Toure, Kate Rogers, Kate Dodson, Anita Sharma, Marta Seoane & Anthony Costello
http://dx.doi.org/10.2471/BLT.16.170431

.
Country perspectives on integrated approaches to maternal and child health: the need for alignment and coordination
Pascal Bijleveld, Blerta Maliqi, Paul Pronyk, Jennifer Franz-Vasdeki, Bennett Nemser, Diana Sera, Renee van de Weerdt & Benedicte Walter
http://dx.doi.org/10.2471/BLT.15.168823

Developing a framework for successful research partnerships in global health

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 7 May 2016]

.
Research
Developing a framework for successful research partnerships in global health
Fiona Larkan, Ogenna Uduma, Saheed Akinmayọwa Lawal and Bianca van Bavel
Published on: 6 May 2016
Abstract
Background
The Centre for Global Health, Trinity College Dublin has as one of its goals, strengthening health systems in developing countries. In realising this goal we work across more than 40 countries with third-level, civil society, government, private sector and UN partners. Each of these requires that different relationships be established. Good principles must guide all global health research partnerships.
An exploratory research project was undertaken with research partners of, and staff within, the Centre for Global Health. The aim was to build an evidence-based framework.
Methods
An inductive exploratory research process was undertaken using a grounded theory approach in three consecutive phases: Phase I: An open-ended questionnaire was sent via email to all identified partners. Phase II: A series of consultative meetings were held with the staff of the Centre for Global Health. Phase III: Data sets from Phases I and II were applied to the development of a unifying framework. Data was analysed using grounded theory three stage thematic analysis – open, axial and selective coding.
Results
Relational and operational aspects of partnership were highlighted as being relevant across every partnership. Seven equally important core concepts emerged (focus, values, equity, benefit, leadership, communication and resolution), and are described and discussed here. Of these, two (leadership and resolution) are less often considered in existing literature on partnerships.
Conclusions
Large complex partnerships can work well if all parties are agreed in advance to a common minimum programme, have been involved from the design stage, and have adequate resources specifically allocated. Based on this research, a framework for partnerships has been developed and is shared.

The Lancet – May 07, 2016

The Lancet
May 07, 2016 Volume 387 Number 10031 p1879-1968
http://www.thelancet.com/journals/lancet/issue/current

.
Editorial
Australia’s offshore refugee policy in disarray
The Lancet
Summary
Australia’s contentious way of dealing with refugees and asylum seekers arriving by boat, long condemned by human rights organisations, has come under renewed attack and public scrutiny. On April 26, the Supreme Court of Papua New Guinea (PNG) ruled that the offshore detention centre on Manus Island, PNG, which had been used by Australia under the so-called Pacific Solution, was unconstitutional and ordered its closure. In its ruling, the court said that the centre violated the detainees’ rights to personal liberty under the PNG constitution.

.
Comment
Mind the gap: jumping from vaccine licensure to routine use
Katherine L O’Brien, Fred Binka, Kevin Marsh, Jon S Abramson
Summary
The contribution of immunisation to improving childhood survival is one of the great achievements of global health. Driving down further infectious disease burden will require new vaccines, many of which have taken decades to develop. We are entering an era where the path from licensure to widespread routine vaccine implementation requires more than efficacy and safety data; policy recommendations for new vaccines may only be realised through implementation research to determine how to most effectively ensure widespread use.

Nature – Volume 533 Number 7601 pp7-138, 5 May 2016

Nature
Volume 533 Number 7601 pp7-138 5 May 2016
http://www.nature.com/nature/current_issue.html

.
Comment
Policy: Security spending must cover disease outbreaks
Tadataka Yamada, V. Ayano Ogawa and Maria Freire call for research and development funding and coordination to counter global infectious-disease threats.

.
Letters
Unique human immune signature of Ebola virus disease in Guinea
Paula Ruibal, Lisa Oestereich, Anja Lüdtke, Beate Becker-Ziaja, David M. Wozniak+ et al.
Fatal Ebola virus disease is characterized by a high proportion of CD4+ and CD8+ T cells expressing the inhibitory molecules CTLA-4 and PD-1, correlating with high virus load; individuals who survive the infection exhibit lower expression of these inhibitory molecules and generate Ebola-specific CD8+ T cells, suggesting that dysregulation of the T cell response is a key component of Ebola virus disease pathophysiology.